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Ethanol is an intoxicant widely available within the UK which has implications for 
the behaviour and capabilities of persons who have consumed even modest 
amounts, as well as significant longer-term health issues. Although the sale and 
consumption of alcohol is subject to legislative restrictions, consumption remains 
widespread in the UK.  
  
Ethanol is recognised as being teratogenic to the developing fetus; while 
awareness of the potential adverse consequences of alcohol consumption in 
pregnancy is increasing, a significant number of pregnant women continue to 
consume alcohol despite national advice to the contrary.   
  
This thesis explores the known effects of in utero alcohol exposure upon the 
unborn child, examines methods of detecting alcohol consumption in pregnancy 
and describes the pattern and prevalence of prenatal alcohol consumption in the 
West of Scotland as measured by ethanol biomarkers in the newborn and by 
confidential postnatal maternal interview. The thesis also explores the potential 
use of routinely stored newborn blood spot cards for retrospective ascertainment 
of prenatal alcohol exposure (PAE).   
  
A total of 840 mothers consented to participate in an anonymised study of 
randomly selected participants, 92.5% of those approached. 827 mothers 
completed a confidential postnatal health questionnaire, including details of 
alcohol consumption in pregnancy and were asked to retain their infant’s first 
stool (meconium) for analysis for alcohol biomarkers. Additionally, if mothers 
agreed and the baby’s heel bled sufficiently, an extra blood spot card was 
obtained on day five, coincident with routine newborn blood spot screening. In 
total 740 meconium samples and 668 dried blood spot cards were returned, of 
which 712 meconium samples and 502 dried blood spots cards were analysable. 
463 recruited mothers had previously delivered a baby and 17.8% of all 
participants had smoked in pregnancy. 46.4% of mothers declared some alcohol 
consumption in pregnancy, the majority of whom did not drink after realising that 
they were pregnant. 114 (13.8%) mothers declared some alcohol consumption 
after 20 weeks’ gestation; in only three cases did this include five or more units of 
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alcohol. Mothers who declared alcohol consumption in later pregnancy were more 
likely to be aged > 35 years and to identify as white British (p < 0.05).   
 
Fatty acid ethyl esters (FAEEs) were identified in all meconium samples with a 
concentration ≥600 ng/g in 39.6%. There was no relationship between maternal 
age, body mass index, socioeconomic status as determined by postcode of 
residence, parity or ethnicity and the likelihood of the infant’s meconium being 
either negative or positive for FAEEs, as defined by a concentration ≥600 ng/g. 
Mothers tended to have been less likely to smoke during pregnancy within the 
group whose infant’s meconium was positive for FAEEs (14 vs 20%, p=0.071). 
Correlation between FAEEs in meconium and self-reported alcohol consumption in 
pregnancy was poor; of the eight mothers that reported drinking at least three 
units of alcohol on any one occasion beyond 20 weeks of gestation, only three had 
an infant whose meconium was positive for FAEEs.  
 
Ethylglucuronide (EtG) was detected in 41.1% of meconium samples and the 
concentration was ≥30 ng/g in 14.5%. There was no relationship between maternal 
age, body mass index, socioeconomic status as determined by postcode of 
residence or parity and the likelihood of the infant’s meconium being either 
negative or positive for EtG, as defined by a concentration ≥30 ng/g. Infants 
whose meconium sample was positive for EtG were less likely to have a mother 
who identified as white British (71.3 vs 81.8%, p=0.028). When infant meconium 
was positive for EtG the mother tended to have been less likely to have smoked in 
pregnancy (13.6 vs 18.5%); this difference was not significant. Maternal self-report 
of any alcohol consumption in later pregnancy did not predict an infant meconium 
EtG concentration of >30 ng/g. When meconium samples positive for both FAEEs 
(≥600 ng/g) and EtG (≥30 ng/g) (n=51) were considered, there was a weakly 
positive correlation between the two biomarkers (Pearson’s coefficient= 0.283, 
p=0.044).  
  
Phosphatidylethanol (PEth) was detectable in 262 (52%) dried blood spot samples, 
with concentrations ranging from 2.4 to 3991.6 ng/ml. When the infant blood spot 
card contained ≥8 ng/ml PEth, the mother was more likely to self-identify as 
white British (86.6 vs 79.1%, p=0.028) and to have smoked during pregnancy 
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(p=0.047). Mothers of infants whose blood spot card contained ≥ 20 ng/ml PEth 
were younger (p=0.023), and their BMI was greater (p=0.038). They were also 
more likely to have smoked in pregnancy (p=0.21).  There was no correlation 
between PEth measured in dried blood spot cards and either FAEEs or EtG 
measured in meconium.   
  
Compared to self-report of alcohol consumption in pregnancy, the sensitivity of 
the individual biomarkers ranged from 11.6% for EtG >30 ng/g to 47.8% for a PEth 
concentration of >8 ng/ml, and specificities ranged from 57.1% (PEth >8 ng/ml) to 
84.8% (EtG >30 ng/g). Using a combination of total FAEEs >600 ng/g and EtG >30 
ng/g had a very high specificity for alcohol consumption either ever in pregnancy 
or only after 20 weeks’ gestation, but a very low sensitivity of 6.7 and 5.3% 
respectively. A combination of FAEEs <600 ng/g and EtG <30 ng/g had a positive 
predictive value of 87% for no alcohol consumption after 20 weeks of gestation.  
 
It is concluded that one in seven mothers delivering in the west of Scotland has 
consumed alcohol in pregnancy beyond twenty weeks’ gestation. Reported 
amounts of alcohol consumed are likely underestimated.   
  
This study indicates that routine use of meconium biomarkers for detection of 
alcohol consumption in pregnancy is not currently justified. Similarly, 
retrospective testing of stored dried blood spot samples taken on day five of life 
cannot be recommended as a measure of assessing PAE. Further work is required 
to explore relationships between alcohol biomarkers in meconium and longer term 
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1.1 Introduction  
Presented in this thesis is a narrative of the consequences of prenatal alcohol 
exposure (PAE) including a brief description of fetal alcohol spectrum disorders 
(FASD). The importance of early diagnosis of FASD is emphasised, including 
potential for alcohol biomarkers as screening tests. Discussion is undertaken of 
how the prevalence each of PAE and FASD have and can be established, 
highlighting potential challenges with this. Consideration of demographic factors 
potentially affecting variation in alcohol consumption will highlight that focused 
interventions may be beneficial in reducing PAE. A brief description of the 
metabolism and teratogenicity of alcohol is presented to understand the 
mechanisms of harm, as well as metabolites which can potentially be utilised as 
alcohol biomarkers.  A literature review of infant alcohol biomarkers focuses on 
establishing appropriate diagnostic cut-off values and combinations of biomarkers 
used for the assessment of PAE in media including meconium and blood spot cards.  
  
Ethanol is an intoxicant widely available within the UK, with implications for the 
behaviour and capabilities of persons who have consumed even modest amounts, 
as well as significant longer-term health issues. Although the sale and consumption 
of alcohol is subject to legislative restrictions, consumption remains widespread in 
the UK, with 80% of adults in the UK reporting consuming alcohol at any time, and 
57% reporting having consumed alcohol within the week prior to interview(1, 2). 
  
Drinking alcohol in pregnancy can cause a wide range of neurodevelopmental and 
other harms to the embryo/fetus and is a leading, but preventable, cause of birth 
defects with lifelong implications(3). PAE (>5 drinks per week) is also associated 
with stillbirth(4).  The effects of PAE manifest as FASD, often associated with 
other co-morbidities including congenital heart disease(5-7). 
  
Appropriate prevention responses are therefore a public health priority. Pregnancy 
offers a unique time in a woman’s life to engage with healthcare services and for 
public health interventions which can impact future pregnancies, care for the 
index child and the woman’s future health. Screening for alcohol consumption in 
pregnancy is recommended by the World Health Organisation but it can be 
difficult for midwives to identify women at risk and many women under-report 
their alcohol consumption(8-10).  A study in Glasgow which tested samples of 
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meconium for alcohol biomarkers in a high risk population found at least a five-
fold higher prevalence of drinking in pregnancy than was self-reported(11).  
Preventive interventions at national level include health promotion and minimum 
pricing. It is important to have a reliable measure of PAE to be able to assess the 
success of current and future government and healthcare interventions.   
  
Biomarkers of alcohol exposure in pregnancy for both mother and infant have been 
identified.  A reliable alcohol biomarker would enable accurate measure of PAE 
both for individuals and at population level.    
  
This thesis describes a research study exploring the use of biomarkers of PAE in 
the infant population within a Glasgow population in order to measure the 
prevalence and also the pattern of PAE. It aims to answer two main questions:  
   
1) are there sociodemographic factors within the West of Scotland which are 
associated with a greater prevalence of PAE, therefore facilitating targeting 
of public health interventions and/or targeted screening for PAE?   
2) is there potential to measure retrospectively PEth in newborn blood spot 
cards as a biomarker for PAE?  
  
 
1.2 Epidemiology of PAE  
1.2.1 Prevalence – UK and internationally  
UK prevalence  
A European cross-sectional study found self-reported prevalence of PAE highest in 
the UK (28.5%)(12). A systematic review of original quantitative studies that 
reported the prevalence in the general population of the respective country’s 
alcohol use during pregnancy from 1984 to 2014 concluded that the UK had the 
fourth highest prevalence of PAE worldwide at 41.3%; 95% confidence intervals (CI)  
32.9-39.0%(13).   
  
Comparison with other countries  
In Toronto one in 10 of the population reports consuming alcohol during 
pregnancy, with one in five drinking while breast feeding(14). There has been a 
recent rise in reported alcohol consumption in the last 30 days among pregnant 
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women in the USA, from 9.2% in 2011 to 11.3% in 2018 (15, 16).   It is estimated 
that world-wide consumption of alcohol during pregnancy is around 9.8% but 
ranging from 0.2-25.2%, with Europe having the highest prevalence (13).  There is 
international variance in the quantification of alcohol with a “unit” being 8 (UK) 
or 14 (US) g of pure alcohol, which must be taken into account when comparing 
studies(17).   
  
1.2.2 National guidance  
In 2016 the United Kingdom’s Chief Medical Officer advised the safest approach to 
drinking alcohol in pregnancy is not drinking at all; this replaced previous advice 
of avoidance of alcohol in pregnancy(18). All women in Scotland should be asked 
about their alcohol intake during their initial pregnancy assessment to allow 
alcohol brief intervention or referral to addictions support(9).  
  
1.3 Consequences of PAE  
A brief summary of the metabolism of ethanol, the handling of alcohol by the 
fetus and subsequent teratogenicity is described as well as how metabolites may 
be utilised as biomarkers.  
  
1.3.1 Alcohol Metabolism  
Ethanol (C2H6O) is a hydrocarbon consisting of one ethyl group (CH3-CH2-) and a 
hydroxyl group (-OH). The ethanol molecule is hydrophilic and crosses cell 
membranes by diffusion. Its metabolism is a complex process dependent on 
movement between fluid compartments within the body and various enzymes with 
variable efficiency. The blood concentration of ethanol is determined by the rates 
of absorption, metabolism and excretion(19). Peak concentration is affected by 
the rate of consumption, strength of the drink, and factors affecting gastric 
emptying and absorption as well as the volume of distribution. Metabolism of 
ethanol is by several oxidative and non-oxidative pathways, with production of 
metabolites which have potentially toxic effects on cell function(20).  
  
20% of ethanol is absorbed in the stomach with the remaining 80% absorbed in the 
intestine(19).  Alcohol is mainly metabolised in the liver but also in a number of 
extra-hepatic tissues such as the brain(19).  Genetic enzymatic variation can lead 
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to variation in both handling of alcohol and alcohol effects upon individuals(19).  
Most of the ethanol directly absorbed from the stomach undergoes first pass 
metabolism by ADH in the gastric mucosa. Variations in gastric ADH related to 
ethnicity and gender exist; the isoenzyme σADH is present in low levels in the 
Asian population compared to the Caucasian population and has lesser activity in 
females(21). First pass metabolism also accounts for the fact that blood alcohol 
concentration is less when alcohol is consumed orally compared to being injected 
intravenously. Gastric ADH function reduces in women following chronic alcohol 
use; the resultant lesser first pass metabolism is thought to contribute to the 
higher incidence of sequelae of chronic alcohol consumption in women(21). 
Normal gut bacteria also demonstrate ADH activity; resultant accumulation of 
acetaldehyde within the gut mucosa may explain gastric symptoms associated with 
chronic alcohol intake(21).  Increased gastric emptying by drugs such as aspirin, H2 
receptors or food consumption, or direct administration of ethanol into the 
duodenum lead to higher peaks in blood ethanol concentration by bypassing first 
pass metabolism(21, 22).  
  
Hepatocytes take up oxygen from surrounding blood, which causes localised 
hypoxia and so hepatocytes surrounding veins are the first to be impacted by 
ethanol(19). It is plausible that this diversion of oxygen from other tissues may 
adversely affect a developing fetus. There are three hepatic pathways for 
metabolism of ethanol occurring in varying intracellular locations: in the cytosol 
(alcohol dehydrogenase - ADH), endoplasmic reticulum, (microsomal ethanol 
oxidizing system - MEOS), and the peroxisomes (catalase). All of these pathways 
produce a toxic molecule called acetaldehyde.  Acetaldehyde is then converted in 
the presence of aldehyde dehydrogenase to acetate.   




Figure 1.1 Pictogram of the metabolism of alcohol to acetate in the liver(21)  (ADH 
- alcohol dehydrogenase, MEOS  - Microsomal ethanol oxidizing system, ROS- 
reactive oxygen species)  
  
ADH is responsible for most ethanol metabolism, both in the stomach and liver. 
Oxidation of ethanol to acetaldehyde and then to acetate by ADH involves transfer 
of a hydrogen molecule to nicotinamide adenosine dinucleotide (NAD), which 
becomes NADH.  The ratio of NADH/NAD influences the concentration of α-
glycerophosphate which affects triglyceride deposition within the liver. A higher 
ratio of NADH/NAD reduces the functional ability of the kidneys to excrete uric 
acid leading to hyperuricaemia.  These cumulative changes contribute to the 
effects of liver disease subsequent to alcohol consumption(21).   
  
ADH has several forms, classified based on the expression of seven genes(21).  ADH 
class I is the most important and absence of this variant is associated with an 
increased likelihood of FASD. By contrast, mothers with more efficient ADH have a 
reduced incidence of children affected by FASD(23).  The risk of FASD within 
different ethnic groups varies, being greater in Afro Caribbean women compared 
to those of Caucasian descent(24).  This risk appears to be independent of the 
volume and pattern of consumption of ethanol.  
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The microsomal ethanol oxidizing system (MEOS), involving cytochrome P-450, 
presents an alternative oxidative pathway for ethanol and is important in the 
presence of high concentrations of ethanol(20). Chronic alcohol consumption does 
not result in increased ADH activity but induces CYP2E1 (of cytochrome-P450)(20, 
21). Induction of CYP2E1 also leads to the production of other hepatotoxic agents 
and the formation of free oxygen radicals.  The oxidative stress caused by this 
process contributes to alcoholic liver disease. MEOS may also lead to localised 
production of acetaldehyde, causing damage at the point of production(20).   
  
Chronic exposure to alcohol is associated with increased malignancy in the 
gastrointestinal and respiratory systems(21).  This may be explained, at least in 
part, by increased cytochrome P-450 activating carcinogens but there is also a 
strong link between alcohol consumption and cigarette smoking(21). Acetaldehyde 
is a highly toxic substance. In the liver, acetaldehyde can bind with proteins to 
produce acetaldehyde-protein complexes which lead to the production of 
antibodies(19, 21). Acetaldehyde also binds to proteins on erythrocyte membranes 
leading to enlarged erythrocytes(21).   
  
There are two non-oxidative metabolic pathways for ethanol. The first produces 
fatty acid ethyl esters (FAEEs) from fatty acids and ethanol. FAEEs persist in 
tissues and play a role in tissue damage(21). The second pathway is the reaction 
between ethanol and phospholipid (phosphorus containing lipid) to 
phosphatidylethanol (PEth) in the presence of the phospholipase D, which has a 
high Km (Michaelis constant, affinity for substrate) for ethanol(19, 21).  I will 
discuss these alcohol biomarkers in the literature review.  
  
In summary, variation in an individual’s ability to metabolise alcohol means that 
the effects of the consumption of alcohol are individualised, with no one cut-off 
defining a safe alcohol intake.  
  
1.3.2 Alcohol distribution and metabolism in pregnancy  
Body water volume of distribution for ethanol is lower in women than in men and 
is further affected by the reservoir of amniotic fluid and the fetal circulation 
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during pregnancy(20). Multiple factors affect kinetics of ethanol in pregnancy, 
including gestation, genetics and placental perfusion(25).  
  
Placental function and ethanol metabolism  
The main three enzymes involved in the metabolism of ethanol; CYP2E1, ADH and 
ALDH are found in placental tissue in varying concentrations and affinities. The 
placenta can therefore metabolise some ethanol.  CYP2E1 has the highest affinity 
of the placental enzymes involved in alcohol metabolism and plays a larger role in 
placental metabolism; activity of CYP2E1 appears to be directly related to 
PAE(26). When ADH has been detected in placenta, it has been class II ADH, with 
lower affinity and reduced metabolic rate and therefore likely not to play a 
prominent role in alcohol metabolism.  ALDH in the placenta also has a lower 
affinity and lower activity than that found in liver tissue. Thus, the placenta 
metabolises alcohol at a much slower rate than other maternal and fetal 
tissues(26).    
  
Fetal absorption of ethanol  
Ethanol in the blood stream of a pregnant mother readily crosses the placenta into 
the fetal circulation via the umbilical cord(25). Due to the highly vascular nature 
of the placenta and the hydrophilic nature of the molecule, ethanol crosses by 
rapid diffusion, and can be detected in the fetus within one minute of ethanol 
presence in the maternal blood stream. By one to two hours following maternal 
consumption, ethanol concentration in the fetal blood stream reaches equilibrium 
with the mother’s blood concentration of ethanol(20, 27). The amount of ethanol 
crossing the placenta is affected by both peak maternal blood alcohol 
concentration and placental perfusion(26).   
  
Having reached the fetus, ethanol is metabolised to several substances which 
include potential biomarkers including FAEE, ethylglucuronide (EtG) and PEth but 
excretion is still largely dependent on maternal metabolism and excretion(24). 
Transfer of ethanol to the fetus varies throughout pregnancy with amniotic fluid 
varying in volume in proportion to the fetus throughout gestation(20). Amniotic 
fluid makes up a larger proportion of the uterine contents during the first 
trimester, reducing to less than a quarter of the contents of the uterine cavity in 
later pregnancy.  Once ethanol is in the amniotic fluid it is held in a closed 
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reservoir, to be diffused or reabsorbed by the fetus(28). Absorption of ethanol 
through swallowing occurs from around 11 weeks of gestation; in the last two 
trimesters, fetal swallowing increases with resultant increased exposure to 
ethanol in the amniotic fluid(20). Ethanol can also be absorbed from the amniotic 
fluid via the intra-membranous pathway, across a very thin amniotic surface into 
the fetal vasculature, at a rate of 200 to 500mls per day(28).   
   
Fetal excretion of ethanol  
Up to approximately 20 weeks of gestation alcohol permeates across the fetal skin 
into the amniotic fluid, but it is also excreted through lung fluid and by excretion 
of urine into the amniotic fluid cavity.  Between 20 to 24 weeks of gestation when 
the skin becomes a more impermeable structure movement of alcohol between 
amniotic fluid and the fetus decreases(20, 28). 
  
The rate of excretion of alcohol from the fetal compartment (based on reduced 
metabolism and dependency of diffusion across the placenta) is approximately 3-
4% of the maternal rate of excretion of ethanol(28). Since diffusion across the 
placenta is bidirectional, the fetus can excrete alcohol back to the maternal 
circulation, but this requires a reduction in the maternal blood alcohol 
concentration and is affected by ongoing maternal alcohol consumption(24).  
  




1.2 Diagram of the fetal circulation and the flow rates of amniotic fluid in ml/day 
demonstrating re-circulating pathways(28). Reproduced with permission.   
  
Fetal metabolism of alcohol  
As noted above, alcohol is cycled through the fetal pulmonary and urinary fluid 
until it is metabolised by the fetus or placenta or removed back into maternal 
circulation.  There are several fetal pathways for metabolism of alcohol, and 
these vary between fetuses(28).  
  
Most fetal alcohol metabolism occurs in the liver. The liver is however not fully 
formed in the first trimester and indeed does not have adult capacity until one 
year of age.  Enzyme function increases throughout gestation; fetal liver, as well 
as lung and kidney tissue, has functioning ADH at two months of gestation but 
enzyme activity is only 3-4% of adult hepatic function.  CYP2E1 has been found in 
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fetal liver tissue from 16 weeks onwards and has a functional capacity of 10-30% 
compared to adult levels of CYP2E1(23). As the fetus has little ability to undertake 
oxidative metabolism of alcohol, metabolism of ethanol depends more on non-
oxidative pathways than in adults(20). FAEE synthesis has been demonstrated in 
placental and embryological tissues of mice, indicating that the necessary 
enzymes are present early in pregnancy(20).   
  
CYP2E1 is present in fetal brain tissue between 7-16 weeks of gestation(20).  
CYP2E1 can produce oxidative free radicals and acetaldehyde within the brain 
tissue which may cause direct neurotoxic effects on the developing central 
nervous system(20). Incomplete metabolism of alcohol in fetal tissue may also 
lead to the presence of toxic chemicals with teratogenic effects(21).   
  
1.3.3 Teratogenicity  
A wide range of teratogenic effects of alcohol have been described(29). The 
mechanisms of harm are multiple, not fully understood and do not appear to be 
directly dose related(29). Teratogenic effects may be caused by alcohol 
metabolites crossing from the maternal circulation (e.g. acetaldehyde) or by end 
products of metabolic pathways in the fetus (e.g. FAEEs)(29).   Although ethanol 
levels in the fetus correlate with maternal levels, acetaldehyde levels do not. 
Despite the placenta providing some protective barrier of oxygenation prior to 
diffusion, maternal acetaldehyde crosses the placenta, where it can accumulate in 
the fetus, including the brain(30).   
  
The organ most affected by alcohol exposure in the embryonic period is the brain.  
This is probably related to the high level of neurogenesis underway, including 
differentiation of cells and the migration of neurones(31). Other confounding 
factors such as nutritional deficiencies and smoking also undoubtedly play a role 
and the timing of alcohol exposure during pregnancy is associated with differing 
teratogenic effects(4). At a cellular level, the teratogenicity of ethanol and its 
metabolites is due to a combination of its effects on cell development, 
neurogenesis, tropic signalling, cell survival and cell death.  Apoptosis of the 
neural crest cells brought about by oxidative stress is considered a plausible 
explanation of the typical fetal alcohol syndrome (FAS) facies(29, 32).  




Ethanol can induce prostaglandin in the fetus, inhibiting growth and resulting in 
lower birthweight. Oxidative stress also has an adverse effect on the enzymes 
directly involved with chromatin structure, potentially leading to epigenetic 
alterations(33).  
  
Teratogenic effects on the central nervous system  
Microcephaly is the commonest structural brain defect identified, but microscopic 
brain changes are also becoming apparent and better understood with improved 
imaging, including both structural and functional magnetic resonance imaging 
(MRI).  Much of our understanding of the teratogenic effects of alcohol comes from 
rodent studies; while rodent brain development is similar to human brain 
development, the rat is born at an earlier stage, with rodent gestation reflecting 
second trimester brain development in humans and the early neonatal period of a 
rodent reflecting the last trimester of human pregnancy(34). Rodents exposed to 
ethanol on day seven of gestation may develop abnormal union of left and right 
midbrain including the corpus callosum, with facial features including abnormally 
closely placed nostrils and long narrow upper lip(34).  Day eight exposure to 
ethanol affects the hindbrain and cranial neural crest cells as well as cranial 
nerves, and larger ventricles can also be identified. Thus, when ethanol exposure 
occurs at these critical early stages of embryogenesis, the affected child will 
present phenotypically with the full clinical picture of FAS whereas exposure later 
in pregnancy may result in few, if any phenotypic effects(29, 35).  
  
A reduction in volume in the corpus callosum is seen in PAE brains, with 
correlation between the macro and micro structural changes and the severity of 
FASD signs and symptoms, including the degree of facial dysmorphology. In 
general, reduction in corpus callosum size is associated with decreased executive 
functioning and impairment of motor skills(35).  
  
The cerebral cortex of PAE brains shows aberrant formation of the gyri and sulci. 
Neurone migration into the cerebral cortex is impaired.  Structural imaging 
identifies atrophy of the frontal cortex and functional imaging identifies deficits in 
frontal, parietal and temporal lobe functioning(35). Subcortical changes include 
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the hippocampus, thalamus and globus pallidus with a strong correlation between 
structural and functional deficits(35).  
  
The cerebellar volume is smaller in PAE affected brains with displacement of the 
anterior vermis and posterior regions. Defects in the cerebellum tend to correlate 
with severity of FASD symptoms, and can present as behavioural difficulties(35).  
Small neuroimaging studies of 12 children with FAS and fetal alcohol effects (FAE) 
have demonstrated reduced overall levels of serotonin. Having reviewed animal 
models it is speculated this may be due to the mechanism of serotonin binding, 
apoptosis of serotonergic neurons or a combination of both factors(36, 37).  
  
Understanding of the effects of ethanol at a cellular level may allow future 
therapies to be considered and implemented(35). Some animal studies have 
investigated whether controlled supplementation of retinoic acid may reduce the 
effects of alcohol on neural cell migration, but this requires caution as high 
retinoic acid levels can in themselves be teratogenic(38).  
  
Twin pregnancies and PAE  
Monozygotic PAE twins had similar phenotypical presentation and IQ scores, 
compared to just over 60% of dizygotic twins suggesting a genetic predisposition to 
the effects of PAE(39, 40) Subsequent work has highlighted some genetic 
mutations predisposing to alcohol induced cerebellar damage, including the 
homozygous mutation of the nNOS gene(41).  
  
Potential contributors/confounders  
Tobacco, cannabis, and cocaine have well described negative effects upon the 
fetus including vascular effects, both in the uterus/placenta and in the fetus 
(arterial occlusion). It has been postulated that impaired uterine blood flow could 
enhance the teratogenicity of ethanol(42).   
  
Nutritional deficiency may also contribute to the adverse effects of PAE and has 
become a focus of research exploring potential dietary supplementation to reduce 
or prevent the teratogenic effects of ethanol(43). Although there is speculation 
that it is the overall reduction in nutritional intake seen alongside alcohol 
consumption which is important, studies are focusing on specific nutritional 
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replacements including vitamin A, choline and folic acid, as well as the role of 
zinc in neuronal development in the fetus(44). There is evidence from the mice 
model that zinc deficiency plays a role in the pathogenesis of FASD(45).   
  
‘Safe’ amounts of alcohol in pregnancy  
There has been a drive in research to identify ‘safe’ levels of alcohol intake in 
pregnancy to be able to guide expectant mothers.  A number of systematic 
reviews have considered the evidence to date, with variable outcome measures of 
alcohol harm including FASD, poor fetal growth and childhood behaviour. A 
systemic review in 2007 of low-to moderate alcohol intake in pregnancy found no 
evidence of harm but was unable to draw conclusions due to weak evidence(46). 
In 2013 a review highlighted binge drinking was common in mothers whose child 
had been diagnosed with FASD and that binge drinking at least twice a week was 
more associated with the phenotype of FASD(47). A further systematic review in 
2016 of low to moderate alcohol intake (32g or four UK units per week) and its 
effect on infants also did not identify specific harms but found that low to 
moderate alcohol intake may be associated with infants being born small for 
gestational age. This review therefore recommended a precautionary measure of 
abstaining from alcohol during pregnancy(48).  Flak et al. in 2014 found that low 
level alcohol consumption (less than daily intake) may affect child behaviour, 
including social engagement, affect and conduct(49).  The findings from this 
review suggested that alcohol harm may occur with less than one drink per day, 
resulting in a recommendation that mothers abstain from alcohol through 
pregnancy(49).  
  
As discussed above the teratogenic effects of alcohol on the fetus are 
multifactorial including the mother’s ability to metabolise alcohol, fetal genetics, 
timing or exposure and nutrition; thus infant phenotype does not directly 
correlate with individual maternal alcohol intake(41-45). Safe levels of alcohol 
intake are therefore likely to be individualised to mother and fetus. Currently the 
advice from the United Kingdom Chief Medical Officers is to abstain from alcohol 
throughout pregnancy(18).  
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1.3.4 Description of FASD/FAS  
PAE places children at risk of FASD, including its most severe presentation, FAS. 
The diagnosis of FAS rests on a triad of criteria including poor growth, specific 
facial features, and central nervous system abnormality in the context of a 
positive history of PAE. As the wider diagnosis of FASD includes conditions related 
to PAE which do not meet the full diagnostic criteria for FAS, the prevalence of 
FASD is considerably greater than the prevalence of FAS. It has been estimated 
that one in 67 children prenatally exposed to alcohol will develop FAS but many 
more will have alcohol related morbidities which do not meet the diagnostic 
criteria for FAS(13). The latter children are commonly undiagnosed(50).   
  
FASD is associated with a wide range of comorbidities and its costs are seen in the 
healthcare, justice, and education systems(51, 52). Earlier diagnosis of FASD 
(before age six years) results in a reduction in secondary complications and 
adverse life outcomes as does stability in childhood, including fewer placements 
and absence of witnessing violence in the household(7, 8, 49, 53). Focused 
interventions may also lead to better outcomes. There is increased likelihood of a 
sibling having FASD, making the case for family screening and intervention when a 
positive diagnosis is made(54, 55).   
  
FASD is often under or misdiagnosed, as the behavioural phenotype overlaps with 
other conditions particularly autistic spectrum disorders (ASD) and activity-deficit 
hyperactivity disorder (ADHD)(50, 56, 57). Guidelines exist for distinguishing the 
different presentations, noting that that children with FASD present a very 
specific profile(57). Healthcare professionals report a lack of knowledge of FASD 
which provides a challenge to ensuring accurate and timely diagnosis, furthermore 
children may have multiple diagnoses; such as ASD in addition to FASD 
complicating a diagnosis(58). The importance of skilled psychology assessment in 
addition to general awareness cannot be overemphasised.  
  
This study described in this thesis concerns the prevalence of PAE, i.e., the 
number of children who are born at risk of FASD because of having been prenatally 
exposed to the potentially teratogenic effects of alcohol.  These children will be 
referred to as infants who have been ‘alcohol exposed’.  
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1.3.5 Prevalence of FASD   
A number of population studies have been undertaken to establish the prevalence 
of FASD as well as FAS. Globally, the estimated prevalence of FASD is 7.7 per 1000 
in the general population, with the highest prevalence in the European region at 
19.8 per 1000(59). McQuire noted in her thesis that in the UK, one study published 
in 2017 estimated that 3.3% (95% CI 2.0% - 4.9%) of children in the general 
population may have FASD, based on the assumption that one in 13 children with 
PAE will develop FASD(59, 60).  A study in the UK applied a novel FASD algorithm 
to pre-collected data and estimated an incidence of FASD of between 6-17%, but 
the true prevalence of FASD is not known(61). It has been estimated that 80% of 
FASD is never diagnosed and that 7% is misdiagnosed as other neurodevelopmental 
conditions(62). Worldwide it is been estimated that 1.5 in 1000 infants are born 
with the full stigmata of FAS(13).   
  
Caution should be applied in comparing reports of the prevalence of FASD as there 
is variability between studies, including diagnostic guidelines. Current FASD 
guidelines include Astley’s 4-digit code, Canadian Guidelines and the more 
recently published Scottish Intercollegiate Guidelines Network (SIGN) guidance(56, 
63, 64).  It is good practice for the diagnostic criteria to be documented in studies 
reporting prevalence of FASD.  
  
Study design also varies, and may include clinic-based studies, passive 
surveillance, and active case attainment. Clinic-based studies will only pick up 
those that engage with services and will, by definition, report higher rates. 
Passive studies use previously collected data such as birth records and can capture 
large populations but are dependent on accurate databases(62, 65). Active case 
attainment utilises population screening to seek out positive cases and is not 
dependent on either existing databases or case reporting as for surveillance 
studies. Active case attainment is expensive and labour-intensive but is likely to 
be the most accurate means of calculating prevalence. It can be used to capture a 
focused population group, e.g., school pupils(62).   
  
In Scotland, it is acknowledged that under-reporting of FASD occurs due to lack of 
knowledge and misdiagnosis as well as poor access to prenatal alcohol history(58, 
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64). During a 60-month period (2010-2015) active surveillance carried out by the 
Scottish Paediatric Surveillance Unit reported 41 cases of FAS, giving a prevalence 
of 0.19/1000 live births(64, 66, 67). There was a reported association with 
maternal smoking and drug misuse(67). A further active reporting study is 
underway by the British Paediatric Surveillance Unit Team (Royal College of 
Paediatric and Child Health)(68).  By comparison, a UK study estimating FASD 
prevalence in the UK identified that a diagnosis of FASD was more common in 
unplanned pregnancies and children of lower socioeconomic background(61).  
  
Prevalence of a condition may depend upon the population selected; special 
education, looked after and accommodated children and prison populations have 
all been recognised as having higher prevalence of FAS/FASD compared to the 
general population. The prevalence of FASD is between 30.5 and 52% in children in 
foster care and between 9.8 and 23.3% in prison settings(69). An estimated 12-23% 
of individuals entering the juvenile justice system have FASD, largely previously 
undiagnosed(70-72).  This high prevalence may explain at least in part common 
impulsive behaviours and difficulty comprehending consequences which Is 
described as part of FASD phenotype.  
  
1.3.6 Cost of FASD  
The financial cost of FASD to the population includes healthcare, education and 
judicial services and is difficult to estimate(52, 71).  Individuals with FASD have 
increased hospital admissions, increased comorbid conditions such as congenital 
heart disease, low birth weight, sensory-neuro hearing loss, alongside a range of 
abnormal neurological findings in keeping with their diagnosis(5). Extra education 
support is often required, and there is potential loss of earning through the 
challenges of employment in the presence of disability. Secondary health 
complications and suicide lead to premature death(52, 54, 73). Taking into 
account all these factors, it has been estimated that the lifetime cost of FASD is 
$1.5 million per individual(52, 74).  
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1.4 Ascertaining PAE  
A number of studies have been undertaken to ascertain the prevalence of alcohol 
intake in the pregnant population, utilising both maternal self-report and alcohol 
biomarkers.  There are however concerns in regard to the accuracy of these 
methods, and thus the accuracy of reported prevalence of PAE. The importance of 
documenting the prevalence of alcohol consumption in pregnancy includes being 
able to measure the effectiveness of public health interventions and make 
preparation for health and education requirements of children with FASD. The 
Scottish Maternal and Infant Study in 2017 reported that younger and more 
deprived mothers were more likely to report alcohol avoidance pre-pregnancy(75).  
45% of mothers reported not drinking in pregnancy of whom 14% never drank and 
31% stopped drinking in pregnancy(75). 54% of mothers reported continuing to 
drink in pregnancy, although 25% cut down the amount of alcohol taken.  88% of 
all mothers who reported drinking alcohol stated that they had stopped drinking 
alcohol when they found out they were pregnant. The survey response was 
however only 30%, with potential for selection bias; younger and more deprived 
women were underrepresented in this survey(75).  
  
A further study in Scotland carried out cross sectional assessment of maternal 
intake using a 7-day retrospective diary(76).  It also found that alcohol 
consumption fell on recognition of pregnancy and that the pattern of drinking 
remained biased towards the weekend. The most socioeconomically deprived 
women drank less than their less deprived counterparts but the patterns in 
drinking also varied with deprivation. Women from more deprived areas tended to 
drink less alcohol but more consistently and women from more affluent areas 
reported exceeding recommended limits for alcohol consumption more often. 
These findings are not in keeping with alcohol harm being greater in poorer 
areas(76). The introduction of minimum alcohol pricing in Scotland has seen a 
reduction in the amount of alcohol purchased per household, particularly in poorer 
families; ascertaining the true impact of this on PAE is difficult without accurate 
assessment of PAE(77).  
  
A population based observational study of 235 mother infant dyads born at the  
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Princess Royal Maternity in Glasgow measured two different alcohol biomarkers, 
FAEEs and EtG, in meconium. This pilot study, carried out by a different 
researcher from the supervisor’s team, provided feasibility for the main study 
described in this thesis, concluded that, based on EtG concentration of >30 ng/g in 
meconium, 15% of pregnancies were exposed to alcohol, despite only 3% of 
mothers reporting alcohol consumption(78). In this study, mothers from more 
affluent areas tended to be more likely to have infants whose meconium 
contained significant amounts of FAEEs, but the difference was not significant(78).   
  
1.4.1 Maternal self-report  
PAE screening by self-report appears to be more accurate soon after delivery 
compared to later in the infant’s life(79). Retrospective diaries have been 
demonstrated to identify higher alcohol consumption(76). However, under-
reporting is a major concern in alcohol screening, with recall bias and worries 
around stigma all being cited(76).  Women commonly underestimate the volume of 
alcohol they are pouring and mothers are reported to underestimate by two thirds 
the amount of spirits they perceive themselves to be drinking(76, 80).  There is 
some evidence that self-report is more accurate when not collected by a 
healthcare provider(76).   
  
There are a range of validated screening tools for alcohol intake; some screening 
only for risky drinking and others seeking to establish more accurate attainment of 
alcohol intake.  AUDIT-C (Alcohol use disorder Identification test) and TWEAK 
(tolerance, worry about drinking, eyeopener, amnesia and cut-back) are screening 
tests which identify at risk drinking(81). Timeline follow back is a retrospective 
diary which documents the amount of alcohol over a period of time, providing an 
accurate report of alcohol intake including variation, e.g., weekdays vs weekends, 
pregnancy vs pre-pregnancy(79, 82). The traditional timeline follow back is 14 
days, however this can be modified to focus on a particular period.  As women 
may change their drinking behaviour throughout pregnancy, a timeline follow back 
method is able more accurately to establish drinking patterns throughout 
pregnancy(79).  This is important when validating alcohol biomarkers formed from 
19-20 weeks of pregnancy onwards. Ascertainment of accurate cut-off values for 
alcohol biomarkers is made difficult by inaccurate self-report and little 
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differentiation between descriptions of “low” or “moderate” alcohol consumption 
through pregnancy.  
  
Lange’s systemic literature review of studies between 1999 and 2005 summarised 
10 population studies of the use of FAEEs in meconium compared to maternal self-
report for the assessment of PAE(83). Nine of the included studies utilised a cut off 
≥600 ng/g; prevalence of positive meconium samples ranged between 2 and 45%. 
There was wide variance from the maternal self-report, which was 0.7 to 43 times 
less likely than a positive meconium sample. The studies included a range of 
methods of maternal self-report, including medical records and questionnaires with 
likely variation in accuracy, but it is reasonable to conclude that PAE is consistently 
underreported to healthcare professionals(83).  
  
1.4.2 Sociodemographic patterns of PAE   
A number of studies have focused on sociodemographic factors in an attempt to 
identify high risk groups of pregnant women. Drinking in pregnancy has been 
associated with deprivation and therefore assumed to contribute to health 
inequalities associated with poverty(84). However, as noted, a recent pilot study 
of alcohol biomarkers in meconium in Glasgow noted a trend towards more PAE for 
newborns of more affluent pregnant women, as did a Scottish government survey 
study of recently delivered mothers in 2017(75, 78). In the latter study younger 
women were more likely to report avoiding alcohol. Across two Scottish health 
boards, more affluent women were more likely to drink alcohol, although as 
already discussed, the pattern of alcohol consumption varied with socioeconomic 
status(76). A pan European cross-sectional study identified higher education and 
smoking as risk factors for PAE(12). A study performed in the United States Centre 
for Disease Control (USCDC) identified that mothers >35 years of age as well as 
mothers who had attained higher education level, were in employment and were 
unmarried were more likely to consume alcohol in pregnancy(85). A 2015 study in 
a Canadian population found that smoking either before or after pregnancy 
increased the likelihood of alcohol use in pregnancy(86). Confirmation of 
sociodemographic predictors of PAE could allow focused public health intervention 
and early screening of potentially affected infants.   
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1.4.3 Alcohol biomarkers   
Since there is no diagnostic test for FASD and maternal self-report of PAE is 
unreliable, measuring alcohol biomarker may be useful in the identification of 
PAE(83). While work has been undertaken in the adult population assessing 
markers of alcohol exposure including mean cell volume, gamma-glutamyl 
transferase (GGT) and carbohydrate-deficient transferrin, caution must be 
exercised in the interpretation of biochemical changes associated with 
pregnancy(87). A study of the prevalence of alcohol exposure in early pregnancy 
based on antenatal booking bloods in a Northern England population demonstrated 
elevated GGT in 4.2% of blood tests analysed, suggesting early pregnancy alcohol 
exposure(88).   
  
Among the range of other biomarkers, measurement of FAEEs in infant meconium 
is reported to be the most promising medium for detection of alcohol biomarkers, 
with studies reporting correlation with neurodevelopmental outcomes(89-91). 
Newly delivered mothers have demonstrated willingness to take part in studies of 
infant meconium as a potential screening tool for PAE, as demonstrated by 
Abernethy et al.(78). Infant biomarkers may be of use for both individual and 
population screening, enabling targeted developmental follow up as well as 
measurement of public health outcomes and could potentially be complementary 
to self-report. Carbon monoxide (CO) measurement is currently used in Scotland 
as an adjunct to self-report for smoking screening in pregnancy. In determining 
PAE, there is potential benefit to the child of early diagnosis of FASD, and for 
family interventions, both sibling screening and removal of risk for future 
pregnancies(7, 54, 92). Validated cut-off values for infant alcohol biomarkers are 
important and so a literature review focusing on infant biomarkers was undertaken 
in order to establish cut-off values for both FAEEs and EtG measured in meconium.   
  
1.4.4 The ethics of screening  
Pregnancy is a unique time when the ethical focus of care changes from one to 
two lives; screening may be undertaken during pregnancy and/or in the newborn 
period.  Pregnancy and newborn screening aim to detect treatable conditions to 
effect better outcome for either or both mother and baby. The primary purpose of 
screening is that it offers benefit to the person being screened(93, 94).  The UK 
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national screening committee has a very specific list of criteria which must be met 
before a screening test is approved; the screening test should provide more 
benefit than harm and should be affordable. For tests of alcohol screening in 
pregnancy and infancy to translate from research to a national screening process, 
the issues should be focused on reliability of testing, changes to outcomes for the 
child, cost to NHS and ethical issues surrounding the use of tissue for screening. A 
screening test should have high sensitivity and specificity for the condition(95).  
  
Informed consent is required for participation in screening and mothers consenting 
to screening of their infant must understand that some tests (including testing for 
alcohol biomarkers in meconium) are actually testing both infant and mother. The 
use of meconium as a screening tool for PAE is non-invasive and therefore 
relatively easy, with no need to consider discomfort to the patient, but limitations 
in terms of both the window in pregnancy which will be screened and the accuracy 
of alcohol biomarkers must be considered(96).    
  
A positive meconium screen for PAE would have both positive and negative 
connotations. On the one hand, a result would be useful in allowing alcohol 
interventions for the mother and potentially earlier assessment with heightened 
awareness of a potential diagnosis of FASD for the infant.  However, there are 
negative social consequences for the mother of positive alcohol screening, and 
more recently a legal case has been bought against a mother for alcohol related 
harm(97). To be useful, national screening of maternal and/or infant biomarkers 
for PAE would need a high uptake and be supported by potential developmental 
interventions for the infant. Women have suggested they would support screening 
when coupled with such follow up(95, 98). However, while a positive screen may 
be of benefit to the infant it may not be of interest for the mother and therefore 
generate a conflict of interest in acting for the patient’s best interest(94). At the 
time of carrying out this research project the infrastructure required to carry out 
developmental screening on a potentially large, identified population of at-risk 
infants was not present. The new SIGN guidelines have however increased 
awareness of FASD in Scotland, and highlighted the importance of accurate 
measure of the prevalence of PAE in order to be able to allocate resources in the 
future(64, 84). 




Newborn blood spot cards are used for screening within the UK as part of national 
screening for treatable conditions, with the conditions screened for recommended 
by the UK national screening committee(93, 99). In the UK informed written 
parental consent which includes storage for future research is required for 
newborn screening(100). Retrospective testing of blood spot cards is undertaken 
with parental consent for certain conditions, including congenital cytomegalovirus 
infection for those children presenting with attributable signs and symptoms. 
However, it is noted that in some countries, concerns regarding potential misuse 
of residual newborn blood spot cards have led to the destruction of these 
cards(100). If an alcohol biomarker can reliably be detected retrospectively in 
stored newborn blood spot cards, this might have potential for helping in the 
diagnosis of children presenting with signs of FASD, particularly if no PAE history is 
available. As noted earlier, FASD is over-represented in accommodated children 
whose mothers may not be available to discuss alcohol behaviours in pregnancy. 
This would raise issues of consent for testing, which would need to be given by the 
parent or legal guardian.  A number of research papers have reported the 
usefulness of measuring PEth in dried blood spot cards as a reflection of PAE for 
surveillance purposes; to date there have been no studies from the UK(101-103).   
  
1.4.5 Measurement of alcohol biomarkers in tissues  
As previously discussed, ethanol is rapidly metabolised in the mother and 
therefore direct assay of ethanol, either in blood or urine cannot be utilised as a 
measure of fetal exposure(27). Biomarkers which have been utilised in the adult 
population to monitor compliance to an alcohol-free lifestyle such as FAEEs and 
EtG may also be measured in the infant. Biomarkers from the fetus/newborn have 
potential not only to provide an absolute measure of PAE but also to reflect the 
effects of PAE upon the fetus.  Confounding factors in fetal exposure, including 
maternal and placental metabolism of alcohol and placental diffusion, mean that 
maternal alcohol consumption may not directly correlate with fetal exposure. 
Media from the fetal compartment which have been considered for the analysis of 
biomarkers to assess PAE including placenta, amniotic fluid, meconium and 
neonatal hair and blood.   Currently no fetal compartment sample is routinely 
screened for PAE in the United Kingdom. Indeed, none of these media is routinely 
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collected, with the exception of a blood sample on day 5 of life for the purpose of 
newborn blood spot screening.  
  
Placental tissue is able to metabolise ethanol independently resulting in 
accumulation of FAEEs(26). Ethanol affects placental and umbilical cord blood 
flow with oxidative stress within the placental tissue a possible mechanism of 
harm(26).  A study of placental FAEEs in combination with maternal self-report 
(AUDIT+) suggested PAE in one third of preterm infants but the authors concluded 
that measuring FAEEs in infant meconium was likely to be a more accurate 
measure of ethanol effects on the infant(104). Collecting placentas for such a 
large population as our study was impractical, as was collection of amniotic fluid. 
Neonatal hair is not a reliable marker of PAE(105). In a study of 99 mother-infant 
dyads both maternal and infant hair as well as meconium were analysed for FAEEs 
and EtG; all samples of hair tested negative for both biomarkers compared to an 
82.2% positivity rate for EtG in meconium(105). Coupled with the difficulties in 
obtaining the 30–50 mg hair required for analysis for FAEE or EtG, neonatal hair 
sampling was not considered appropriate for this study.   
  
The majority of data in regard to alcohol biomarkers in the newborn relate to 
meconium, the first stool passed by the infant. Meconium is formed from 
epithelial tissue, bile and hair and consists of 60-80% water(106).  It accumulates 
from 16-20 weeks’ gestation onwards and increases exponentially in weight 
throughout the pregnancy. Meconium is passed by the infant within 72 hours of 
birth, generally in the first 24 hours. It is considered a waste product and is not 
routinely collected. Three quarters of the baby’s meconium is attributed to last 
eight weeks of pregnancy, but analysis of any meconium passed after birth will 
potentially reflect alcohol exposure from 16-20 weeks of gestation. Meconium 
should be sterile, although rarely it can be contaminated by bacteria.  The two 
main alcohol biomarkers explored to date in meconium include FAEEs and 
EtG(106).   
  
In a systematic review of objective measures of PAE published in 2016, McQuire et 
al. noted a high risk of bias and selective outcome reporting. Studies including 
three different cut off values of total FAEEs of 600 ng/g, 1000 ng/g and 10,000 
ng/g and utilising combinations of 4, 6 and 9 FAEEs respectively were 
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examined(107). A total concentration of 4 FAEEs in meconium of ≥600 ng/g 
demonstrated the highest sensitivity for PAE (100%), but with very variable 
specificity (13 – 98%). However, while McQuire found FAEE in meconium to be one 
of the most promising biomarkers of PAE, there was insufficient evidence to 
support the use of objective measures of PAE in screening(91).  The variable 
specificity of FAEEs in meconium led to a concern about a high number of false 
positives which could lead to a burden on both mother and healthcare(91). It was 
concluded that while there was insufficient evidence to support the use of 
objective measures of PAE in clinical practice, biomarkers in meconium merited 
further investigation. 
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1.5 Literature review  
A literature search was undertaken based on current Cochrane guidelines for 
literature reviews. The aim of the search was to review infant biomarkers of PAE, 
specifically appropriate cut off values of specific biomarkers.  The search for 
studies was undertaken from two databases: Embase 1947 to 2021 and Ovid 
Medline 1947 to February 2021. Discussion was undertaken with a librarian at the 
University of Glasgow and other databases were not used to avoid overlap and 
duplication.  Journals were restricted to English language, full text.  The key 
words utilised from the search terms included: foetal, fetal, pregnancy, infant, 
FASD, FAS, fetal alcohol syndrome, fetal alcohol spectrum disorder, alcohol, 
ethanol drink, biomarkers, fatty acid ethyl esters, ethyl glucuronide, 
phosphatidylethanol, FAEEs, EtG, PEth. Boolean logic was utilised for search terms 
to focus the search.  
  
The study generated 618 references; once duplicates were removed this left 504 
studies of which 399 were excluded based on their title. A further eight relevant 
studies were identified subsequent to the literature search. Included studies were 
primarily population recruitment of maternal-infant dyads with collection of 
meconium and/or blood spot cards for analysis of biomarkers (FAEE, EtG and/or 
PEth) as a measure of PAE.  
  
Articles which had titles of relevance (113) had their abstracts reviewed, and from 
them 59 were selected for full paper review.  20 relevant articles were 
categorised by their primary biomarker of interest and reviewed by two 
researchers (including myself and one of my supervisors) to extract relevant 
information.  Papers were tabulated and evidence summarised including methods 
and cut-off values utilised for each biomarker. Additionally, we considered 
whether the cited cut-off value had been derived from self-reported PAE within 
the study populations or adopted based on previous studies. All data were 
reviewed after being compiled into a table.  




Figure 1.3 PRISMA diagram of literature review for infant biomarkers of prenatal 
alcohol exposure 
Within the 20 studies included studies were: six studies with primarily FAEEs 
measured in biomarkers, seven studies of EtG in meconium (one also included 
FAEEs) and eight studies of PEth measurement in blood spot cards. Papers 
describing the same population were excluded. 
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1.5.1 Fatty Acid Ethyl Esters   
FAEEs are direct metabolites of ethanol, formulated through non-oxidative 
pathways in the presence of FAEE synthase and ethanol acyl-O-transferase 
enzymes. They can be produced from both exogenous and endogenous ethanol.  
FAEEs are more hydrophobic than regular fatty acids and therefore can cross the 
cell membrane with relative ease(108). They are transported in blood by 
lipoproteins(109). As FAEEs cannot cross the placenta, FAEEs present in any fetal 
samples represent fetal production(110). FAEEs affect cellular proliferation and 
impair the synthesis of proteins(109). It is hypothesised that FAEEs may 
themselves be mediators in the pathogenesis of alcohol-related end organ damage 
and therefore may contribute to the teratogenicity of ethanol(90).   
Higher levels of FAEEs in meconium have been correlated with lower educational 
attainment and lower IQ scores(89). Within a population of 191 mainly African 
American children of low socioeconomic background followed up through 
childhood and adolescence, higher concentrations of 4 FAEEs (ethyl myristate, 
ethyl oleate, ethyl linoleate and ethyl linolenate) in meconium were related to 
lower Wechsler intelligence scores and full-scale IQ scores(89). The author 
acknowledged limited correlation with maternal self-report of alcohol 
consumption in pregnancy and also noted that higher concentrations of FAEEs in 
meconium were related to higher birth weights.    
  
Endogenous alcohol production results in a low level of FAEEs in meconium, 
therefore requiring the establishment of a cut-off values for the assessment of 
maternal alcohol consumption(111).  Endogenous alcohol production occurs as a 
by-product of the normal microflora of an adult gut and ethanol is also a by-
product of yeast and bacterial infections, with increased production of FAEEs in 
chronic infections(111).There are additionally some dietary effects as olive oils 
contain FAEEs in varying concentrations(111).  Production of FAEEs in meconium 
may occur due to bacterial contamination as gut flora are established in the 
infant(112).   
  
The first description of FAEEs in meconium was in an abstract by Mac et al., 
published in 1994.  They reported on 25 meconium samples, of which 15 were 
from PAE newborns, and demonstrated higher FAEEs (ethyl laurate, palmitate, 
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stearate) in the alcohol exposed samples. Their conclusion was that FAEEs in 
meconium might be a promising biomarker for PAE.  
  
Subsequently there have been a number of population studies seeking to establish 
the prevalence of PAE by measuring FAEEs in meconium. These studies have 
investigated a range of between three and nine FAEEs, either comparing individual 
concentrations or cumulative concentrations of differing combinations of FAEEs. 
They have utilised various values to define a ‘positive’ sample, ranging from 50 to 
10,000 ng/g. There has been variability in study populations although all have 
been hospital based, either single sites or multi-centred. Some studies have 
included control populations allowing comparison of meconium from alcohol 
exposed infants and those that had not been exposed.  Ostrea et al. focused on 
individual biomarkers and found ethyl linoleate correlated with maternal self-
report(113). Pichini et al. recruited from seven different hospitals across Italy and 
Spain and were able to demonstrate significant geographical variance in FAEEs in 
meconium(114). They related these findings at least in part to public health work; 
despite repeated analyses no FAEEs were found in meconium from babies born in 
areas in which a strong public health message had been delivered regarding the 
dangers of PAE(114).  
  
One important consideration is the definition of a positive sample; research papers 
which have compared concentrations of FAEEs in meconium with maternal self-
report are summarised in table 1. These five studies have used differing 
populations and differing methods for ascertainment of self-reported alcohol 
consumption as well as having differing proportions of PAE and non-exposed 
newborns.   
  
Bearer et al. carried out testing on 248 meconium samples screening for eight 
FAEEs, and categorised mothers by alcohol exposure following postnatal 
questioning(115).  They identified that ethyl linoleate was the FAEE of the eight 
which had the most presence in meconium of those infants whose mothers 
reported one or more drinks in the last trimester, but they did not establish any 
cut-off values for the biomarkers(115).  The same research group then carried out 
a small study of 27 mothers and infant dyads screening meconium for three 
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individual FAEEs (ethyl palmitate, ethyl oleate and ethyl linoleate) compared to 
time line follow back ascertainment of alcohol consumption in the second and 
third trimester and found that ethyl oleate had a sensitivity of 84.2% and 
specificity of 83.3% for an alcohol intake of at least 42 g per day(116).  
  
Chan et al. in the same year compared meconium concentrations of FAEEs to 
maternal self-report of PAE to establish appropriate cut-off values and 
sensitivity(111). They compared meconium samples from two non-drinking 
pregnant populations in Toronto and Jerusalem (208 mothers in total) with six 
meconium samples from known PAE infants(111). FAEEs were present in all 
meconium samples and a cut of off 600 ng/g (2 nmol/g) for a cumulative 
concentration of 4 FAEEs (ethyl palmitate, ethyl stearate, oleate and linoleate) 
provided the best sensitivity (100%) and specificity (98.4%) for the detection of 
PAE. These 4 FAEEs were utilised by English et al with a cut off 600ng/g in a 
Ugandan population of 505 women and infants, however found higher detection of 
PAE by TWEAK questionnaire than FAEE in meconium (16% vs 2%)(117). Bearer’s 
work on ethyl linoleate was further confirmed by Ostrea et al. in 2006; in a larger 
case control study of 124 maternal infant dyads ethyl linoleate was linearly 
associated with PAE as ascertained by screened by MAST, CAGE and TACE 
screening tools(113). The sensitivity of ethyl laurate >0.05 µg/g (LOD) was 26.9% 
and the specificity 96.8%(113).   
  
Yang et al. carried out a prospective cohort study including 182 meconium samples 
from infants of alcohol abstaining mothers and 54 samples from “light to 
moderate” drinking mothers(118). At 34 weeks’ gestation mothers completed an 
electronic questionnaire with regards to their alcohol intake, to try to reduce 
response bias. Women were classified as light risk (< three drinks per week) and 
moderate risk (3-7 drinks per week) as per the United States National Institute on  
Alcohol Abuse and Alcoholism (USNIAAA) with 1 drink equating to 14 g of ethanol 
(just less than two UK units). Utilising a total of nine FAEEs (ethyl laurate, 
myristate, palmitate, palmitoleate, stearate, oleate, linoleate, linolenate, 
arachidonate), the authors found no difference between meconium samples from 
infants of abstainers and drinkers. They noted a linear increase in FAEEs above a 
threshold of three drinks per week, but this was based on only two cases.  Yang’s 
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conclusion was that low to moderate alcohol intake during pregnancy cannot 
reliably be assessed by measurement of FAEEs, but that there may be a linear 
relationship between FAEE concentration in meconium and PAE above a threshold 
of three drinks (approximately 42 g) per week(118).  
  
Kwak also measured the total of nine FAEEs in a Korean cohort study(119). Mothers 
provided an alcohol history at 34 weeks’ gestation via an electronic form and were 
categorised based on their self-report as low, moderate, and high-risk drinkers as 
per the USNIAAA.  38.1% of mothers reported alcohol consumption in at least one 
trimester of pregnancy, the majority of whom were light drinkers. The authors 
explored different cut off values for a total of FAEEs in predicting PAE as self-
reported; 600 ng/g had a sensitivity of 22.2% and specificity of 73.6%, 3000 ng/g a 
sensitivity of 5.6% and a specificity of 94.5% and 6000 ng/g a sensitivity of 3.7% 
and a specificity of 98.4%.  The authors found no correlation overall between self-
report of alcohol consumption in mid-late pregnancy and presence of any FAEEs in 
meconium(119). With a cut off of 6000 ng/g however, total FAEEs in meconium 
correlated with both the amount and the frequency of self-reported alcohol 
consumption. Their conclusion was that assumption of PAE in the absence of self-
report could only safely be made with a cumulative FAEE concentration of 
>6000ng/g.  
  
Himes et al. related meconium FAEEs to maternal self-report of alcohol 
consumption in pregnancy for 107 mother and infant dyads(120). They utilised the 
timeline follow back method to establish maternal PAE, considering alcohol type, 
amount, and duration. They applied questionnaires four times between six weeks’ 
gestation and one month post-delivery; mothers were also questioned about pre-
pregnancy alcohol consumption.  Alcohol consumption beyond 19 weeks of 
pregnancy was designated as positive exposure (i.e., during the period of 
meconium formation).  58 women drank after 19 weeks’ gestation, of whom 45 
women drank into their third trimester.  Nine FAEEs were assayed; the authors 
measured individual FAEEs then carried out summation of four, six and nine FAEEs.  
A cut off of 200 ng/g for four FAEEs (myristate, palmitate, oleate and stearate) 
yielded the highest prediction of PAE with a sensitivity of 64.9% and specificity of  
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51.4% (prevalence 34.6%).  Himes et al. acknowledged that self-report was likely 
to be unreliable, and suggested EtG as the gold standard(120).  
  
Bakhireva in 2014 in a study including both PAE infants and non-PAE infants 
established PAE by detailed maternal self-report through timeline follow back 
method over a two-week period from the month prior to the last menstrual 
period(121). Non-alcohol exposed control subjects were recruited for comparison. 
The study group compared various cut offs and combinations of FAEEs that had 
previously been reported in the literature including 600 ng/g (four FAEEs), 10,000 
ng/g (seven FAEEs) and 100,000 ng/g (nine FAEEs). They concluded that a 
cumulative concentration of four FAEEs (ethyl palmitate, stearate, oleate, 
linoleate) ≥ 600 ng/g was the best outcome of all the combinations with a 
sensitivity of 100% for detection of PAE, although with much lower specificity 
(12.5%) than reported by Chan.  
  
The evidence indicates that significant amounts of FAEEs in meconium are 
reflective of PAE, but only reliably so with higher consumption of alcohol (40 g per 
week) While there is some lack of consensus in the literature regarding the best 
cut off for the concentration of FAEEs, a cumulative concentration of > 600 ng/g 
for four FAEEs is probably the most reliable(111, 121). Pichini et al. described the 
method of liquid chromatography-tandem mass spectrometry (LC-MS/MS) when 
comparing prevalence rates between different European populations and found 
less than 10% degradation of the samples on defrosting and analysis, ensuring the 
feasibility of storing frozen samples for batch analysis(122).  
  
Potential problems with measurement of FAEEs:  
The majority of studies undertaken to date do not discuss potential consent bias 
within the recruited population.  Zelner et al. undertook a population study in 
2012 reviewing mothers’ willingness to take part in a study with clinical follow up 
of infants based on the meconium results and compared this to a previous 
anonymous study in a geographically similar population(123).  The number of 
meconium samples positive for FAEEs dropped from 30% to 3% between the two 
studies, potentially reflective of ‘tactical refusal’ by alcohol consuming mothers. 
Mothers may be reluctant to disclose a history of alcohol consumption to 
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healthcare workers due to guilt and/or fear of repercussion as evidenced by Lange 
et al., who found significant differences between PAE measured by self-report and 
by meconium biomarkers. Therefore, biomarkers including FAEEs in meconium are 
more likely to accurately reflect PAE in a population if collected anonymously(83).   
  
FAEEs measured in meconium can be falsely positive, more commonly in delayed 
sampling(112). Zelner at el. demonstrated by serial testing of 136 meconium 
samples from 30 neonates (all initially negative) that the average time for FAEEs 
to become positive in meconium samples was 59.2 hours(112). FAEEs are thought 
to be produced by bacteria in the meconium in samples when analysis has been 
delayed. While meconium is sterile in utero, once the infant has passed through 
the birth canal and feeding is established, natural gut flora will begin to colonise 
the gut(112).  Spiking meconium samples with glucose in vitro results in previously 
negative samples of meconium becoming positive for FAEEs. Therefore, to avoid 
false positive results, samples should be taken as early as possible after birth and 
frozen (discussed in Methods). Many studies do not report the timing of collection 
and analysis of the meconium samples, which result in confounding in those 
studies with delayed sampling.  
































































































1.5.2 Ethyl Glucuronide  
EtG in a non-oxidative metabolite of alcohol which has been measured in urine, 
blood, placenta, and meconium.  EtG has been reported to be a more reliable 
alcohol biomarker than FAEEs, as it is less prone to variation due to nutritional 
factors and/or endogenous production(120). With fewer false positives, specificity 
of EtG as an alcohol biomarker is greater than for FAEEs. EtG is measured by LC-
MS/MS and is stable at room temperature and will remain stable for up to three 
freeze-thaw cycles, although samples should be well mixed prior to analysis(106, 
124).  
  
EtG in meconium has been linked to developmental outcomes with IQ lower on 
average by six points in a cohort of primary school age children with ≥154 ng/g EtG 
in their meconium. In the same study there was a correlation between meconium 
EtG concentration and ADHD related behaviours(125). Clinical findings were not 
related to maternal self-report of alcohol consumption. Elevated EtG in meconium 
has also been correlated with methylation of genes associated with cognition and 
attention deficit, suggesting that PAE in late pregnancy may effect epigenetic 
changes(126).  
  
Identifying a cut off value for EtG in meconium  
There are a number of publications which overlap in the analysis of both FAEEs and 
EtG in meconium. Several of these papers come from the same team based in Italy 
and Spain and include some overlap in subjects which made data extraction 
difficult.  Authors have sought to validate EtG in meconium either by comparison 
with maternal self-report or by comparison with FAEEs in meconium or a 
combination of the two. Relevant papers are summarised in table 1.2; I will briefly 
discuss both the method(s) of validation and suggested cut off values.  
  
The first report of EtG being detected in meconium as a potential marker of in 
utero exposure to alcohol was by Pichini et al. in two populations in Spain and 
Italy. They analysed 173 meconium samples from infants admitted to neonatal 
units and reported the presence of EtG as well as FAEEs(127). There was a 
significant difference between the two populations in the likelihood of meconium 
being positive for FAEEs, as defined by a total concentration of seven FAEEs of >600 
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ng/g). Babies born in Barcelona were more likely to be positive for FAEEs in 
meconium compared to those born in Reggio Emilia (41.9 vs 8.3% of samples); 
median concentrations of EtG in meconium in these two populations were 152.3 
ng/g and 17.6 ng/g, respectively. There was no direct correlation between EtG and 
FAEE concentrations.  
  
The same research group carried out a population study using both maternal self-
report and FAEEs in meconium to try to define cut-off values for EtG in 
meconium(128). 185 meconium samples were obtained with mothers divided into 
two cohorts based on a structured questionnaire regarding alcohol consumption. 
Unexposed infants were defined as those with no PAE reported and a meconium 
FAEE concentration of <600 ng/g. EtG was detected in 83.3% of all meconium 
samples(128).  A cut of value of 440 ng/g for EtG in meconium was reported to be 
100% sensitive and specific for PAE as determined by both FAEEs in meconium and 
maternal self-report.  In 47 meconium samples collected from infants in a single 
Spanish centre there was a correlation between FAEE and EtG concentrations in 
meconium above an EtG cut-off of 50ng/g.  
  
A study in a randomly selected German population found 16.3% of 596 samples to 
have detectable EtG where 10 ng/g was the limit of detection (LOD) for EtG. 
Samples were kept frozen (-20C) and retested at 3 months and found to be 
relatively stable in terms of EtG concentration(106). By comparison, analysis of the 
same meconium samples found 7.1% of samples were positive for FAEEs as defined 
by a total concentration of >500 ng/g for four FAEEs(106). The authors found a 
good correlation between the two biomarkers when including all results (FAEE >100 
ng/g and EtG >10 ng/g) (Pearson’s co-efficient 0.367; P=0.003). Optimal agreement 
between the two biomarkers was described with FAEEs > 500 ng/g and EtG > 274 
ng/g(106).  Two standard questionnaires (FRAMES and CAGE) were used to 
determine maternal self-report of alcohol consumption in pregnancy but only six 
subjects were positive via CAGE. There was very poor correlation between EtG in 
meconium and maternal self-report, interpreted as inaccurate self-report.  
  
In a further prospective cohort of 557 women in Germany, 21.2% reported low to 
moderate alcohol intake in pregnancy (FRAMES)(129). Alcohol intake was assessed 
in detail both during and after pregnancy (soon after delivery and at 6-8 months 
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postpartum).  EtG concentration in meconium was compared with self-report and 
with multiple sociodemographic factors, using either presence or absence of EtG or 
a cut of 120 ng/g to delineate a positive. There was no difference in 
sociodemographic factors between the mothers who did or did not consume 
alcohol, apart from alcohol consuming mothers being less likely to be married. It is 
not clear how the cut of 120 ng/g of EtG was selected.  A further study published 
in 2016 by the same research group reviewed 180 meconium samples from a 
randomly recruited population(79).  EtG concentration varied from 17 ng/g to 
10,235 ng/g. A cut off value of 120 ng/g was utilised which correlated with self-
report of prenatal alcohol consumption (14% of samples; p<0.01)(129). When 
women reported any alcohol consumption, EtG concentration in infant meconium 
was on average 1.8 time higher than for infants of mothers that did not report any 
alcohol consumption. Women were more likely to self-report alcohol consumption 
in pregnancy directly after birth than retrospectively, at 6-8 years post-
partum(79). Agreement between FAEE and EtG was identified when Carbarcos et al 
analysed both biomarkers in the same sample, utilising the cut off value of 600ng/g 
for FAEEs but not identifying a cut of value for EtG(130). 
 
Up to this point cut-off values identified for EtG were conservative, focussing 
primarily on specificity.  Himes et al. analysed 107 meconium samples as part of 
the Safe Passage study from the Northern Plains, USA and Cape Town, South 
Africa(120). Detailed self-report by timeline follow back method was carried out on 
five occasions throughout pregnancy to establish alcohol intake and four cohorts 
were identified (no alcohol consumption, nil in third trimester, average 3-10 drinks 
per drinking day (DPDD) after 24 weeks’ gestation and average >10 DPDD 
(equivalent to approximately 140 g alcohol) after 24 weeks’ gestation. There was a 
weak association between FAEEs (sum of either four, seven or nine) and EtG as well 
as a dose concentration relationship with EtG for alcohol consumption after 19 
weeks’ gestation. A cut-off concentration of EtG of ≥ 30ng/g yielded the highest 
sensitivity (81.8%) and specificity (75%) compared to other biomarkers including 
ethyl sulfate and cumulative FAEE combinations(120). In validating maternal hair 
EtG, Joya et al. from the Spanish research group subsequently acknowledged that 
the cut-off value for EtG in meconium should be reduced to 30 ng/g (106, 120, 
131).  




Since Himes et al. there have been a number of population studies describing the 
prevalence of PAE based on the use of EtG as a biomarker in combination with 
either self-report or another alcohol biomarker(120). These have included a Navajo 
population (prevalence of any EtG in meconium 5.1%) and a Glasgow population 
(prevalence of EtG > 30 ng/g in meconium 15%)(78, 132).  Measurement of EtG by 
enzyme-linked immunosorbent assay (ELISA) is a more rapid and inexpensive 
measurement than LC-MS/MS; in this study by Pichini et al., a cut off value of 200 
ng/g (0.9 nmol/g) EtG as measured by ELISA was 100% sensitive and 78% specific for 
the detection of PAE in a cohort of babies born to known alcohol consuming 
mothers(133). 




























































































 1.5.3 Phosphatidylethanol (PEth)  
Phosphatidylethanol (PEth) is a glycerophospholipid present within the red blood 
cell membrane, which is formed from ethanol by the enzyme phospholipase(134).  
Fatty acid chain lengths can be either 16, 18 or 20. PEth 16:18.1 (1-palmitoyl-
2oleolyl-sn-glycero-3-phosphoethanol) is a reliable biomarker in the adult 
population with a dose-response relationship(134). In healthy adult subjects PEth 
has a half-life of four to 12 days, however this half-life varies; in alcoholic subjects 
the half-life of PEth is four days. While PEth measured in adult blood is a very 
sensitive measure of high alcohol exposure, caution has been expressed about the 
detection of low to moderate alcohol exposure, with cut off values close to the 
LOQ. Several studies have reported that assay of PEth concentration in the 
newborn may provide a measure of PAE in the last trimester of pregnancy with a 
reported specificity of 100%(121).  
   
Details of seven papers and one abstract exploring the use of PEth assayed from 
dried blood spot cards obtained from newborn infants as a measure of PAE are 
presented in Table 3.  As a validated method of ascertaining PAE, PEth measured 
from a dried blood spot card would be particularly useful in population studies 
since dried blood spot cards are already obtained from almost all of the newborn 
population and routinely stored for retrospective testing.  Synthesis of PEth has 
been reported not to occur in blood spot cards post collection(135).  
  
Bakhireva et al. undertook a feasibility study in 2013 of 201 randomly obtained 
blood spot cards for measuring PEth with a view to population screening for 
PAE(102). 87.6% of blood spot cards had sufficient blood and yielded a PEth result. 
The LOD for PEth was 8 ng/ml. This paper also reviewed the stability of PEth in 
dried blood spot cards over time, reporting 96.3% stability at three months from 
collection(102). The cost of analysis of dried blood spot cards was approximately 
half that of analysis of meconium for FAEEs ($61.10 vs $112.69).   
  
There is variation between published studies in cut off values used to define 
positive samples. Both 8 and 20 ng/ml have been utilised by Bakhireva’s group 
whereas 20 ng/ml is suggested by the United States drug testing laboratories 
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 (USDTL) as a positive result in adult samples(102, 121).  
  
The same group tried subsequently to validate PEth in dried blood spot cards by 
using 60 dried blood spot cards from 28 PAE newborns and comparing them with 32 
non-alcohol exposed newborns. PAE was also assessed by meconium testing for 
FAEEs and maternal self-report (AUDIT-C & time line follow back-14 days)(121). 
32.1% of blood spot cards obtained from PAE newborns had a PEth concentration ≥ 
8ng/ml (LOD) compared to none in the control group. The specificity of PEth in 
dried blood spot cards was 100% compared to a specificity of 12.5% for a FAEE 
concentration of >600 ng/g (ethyl palmitic, stearic, oleic, linoleic) in meconium 
within the same population. The sensitivity of PEth was 32.1% compared to 100% 
for FAEEs(121).   
  
Baldwin et al. presented an abstract describing 346 blood spot cards collected 
anonymously and at random in the Midwest. These dried blood spot cards were 
filled from umbilical cord blood at the time of delivery. 19.7% of samples were 
deemed positive (PEth >8 ng/ml)(136). The same team went on to publish a study 
of 250 residual dried blood spot cards taken at the same time as newborn screening 
(24-48 hours of age) from a similar population and obtained from the department 
of public health; PEth concentration was ≥8 ng/ml in 4%(137). PEth concentration 
was not compared to maternal self-report in this anonymised study which 
established the feasibility of carrying out retrospective testing on dried blood spot 
cards obtained for the purpose of newborn screening(137). Stability of dried blood 
spot cards when stored at room temperature over a 12 month period was 65.9%, 
with evidence that stability begins to diminish after six months at room 
temperature(137).  
  
Bakhireva et al. carried out a larger, anonymised study of 1000 residual dried blood 
spot cards obtained within the state of Texas (40% Hispanic population)(138). 
Utilising a cut-off of ≥20 ng/ml as per the USDTL, the positivity rate was 8.4%. 
Large regional differences were detected within this population with a higher 
prevalence of raised PEth in urban areas and within the Hispanic population, and a 
trend to increased prevalence of a PEth concentration >20 ng/ml in more affluent 
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areas. This study did not attempt to correlate PEth values with self-reported PAE as 
the samples were obtained anonymously from the newborn screening lab.  
  
In a recent (2019) cohort of 162 infants, dried blood spot cards were used to 
compare PEth in umbilical cord blood with EtG in umbilical cord tissue in a 
department where practice was to screen cord tissue for EtG at physician 
discretion. 26.5% of dried blood spot cards had a PEth concentration of ≥8 ng/ml 
compared to universally negative EtG cord tissue.  Results were not compared to 
maternal self-report.  There was no association with maternal demographics or 
infant Apgar scores and PEth concentration in newborn blood spot cards(139).  
  
The largest study published to date measuring PEth in dried blood spot cards was 
carried out across two sites (Uruguay and Brazil) and utilised dried blood spot cards 
obtained from both mothers and their newborns(140).  Infant blood spot cards were 
obtained at 24–48 hours of life. Using a cut-off of ≥8 ng/ml PEth to define a 
positive sample, there was variation between maternal and infant blood spot cards; 
Uruguay 86.8% positive in newborns and 45.8% positive in maternal blood spot cards 
and Brazil 76.9% positive in newborns and 43.9% positive in maternal blood spot 
cards. The explanation for this difference is not clear although mothers would only 
be expected to have a positive sample if they had consumed alcohol within 48 
hours of delivery(140). Only 13% of mothers reported third trimester alcohol 
consumption.  
  
Umer et al. published in 2000 a large study of 1830 residual dried blood spot cards 
obtained in West Virginia which were anonymously linked with maternal 
demographics(141). PAE as defined by PEth >8 ng/ml was associated with smoking, 
preterm births, lower birth weight (<2000g vs >3000 g) and with mothers not 
wishing to exclusively breastfeed(141).  
  
In summary, the assay of PEth in infant dried blood spot cards is relatively new and 
has only been validated in a small study of 28 PAE infants and 32 controls(121).  
The timing of blood sampling has been either at birth or between 24 and 48 hours 
of life, coincident with routine newborn screening(102, 142).  Of note, this is 
different timing from the obtaining of dried blood spot cards within the UK which is 
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carried out between 96 and 120 hours of age. To date no study has reported PEth 
values in dried blood spot cards obtained within 96 to 120 hours of life. Neither has 
any study to date reported on developmental outcomes of infants with detectable 
PEth in blood samples at, or soon after birth.  
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1.5.4 Conclusions  
There are significant concerns around the accuracy of maternal self-report of 
alcohol consumption in pregnancy, especially when sought retrospectively. While it 
might be anticipated that sociodemographic factors are associated with 
consumption of alcohol in pregnancy, this has not been consistently demonstrated. 
Identifying sociodemographic factors predictive of at-risk populations would allow 
focused public health interventions.   
  
Meconium has potential for measurement of alcohol biomarkers, and both FAEEs 
and EtG in meconium have been correlated with neurodevelopmental outcomes. 
FAEEs in meconium can however be unstable, related to dietary factors and 
affected by bacterial contamination(120, 143).  Similarly, to screening for smoking 
in pregnancy with self-report and CO measurement, it may be that alcohol 
biomarkers can complement maternal self-report of alcohol consumption. This is 
most likely for unidentified high consumers of alcohol who have not disclosed 
alcohol consumption. Using appropriate, validated cut-off values for alcohol 
biomarkers is key, and there is evidence that use of more than one biomarker may 
be helpful.   
  
The potential use of newborn blood spot cards to measure PEth needs further 
investigation. As these cards are routinely collected and stored in the UK, there is 
potential to measure retrospectively PEth concentration in the newborn period in 
children presenting with features of FASD, particularly if a maternal history of 
alcohol consumption is unavailable.   
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2.0 Methods  
2.1 Aim  
The primary aim of this observational population-based study was to examine the 
pattern and prevalence of alcohol consumption in pregnancy as determined by 
infant biomarkers among women delivering at the Princess Royal Maternity (PRM) in 
Glasgow.  Additionally, the research study sought to examine the potential for 
newborn blood spot cards to be tested retrospectively as a marker of PAE.  
  
2.2 Study population and protocol development   
PRM is a tertiary level maternity facility serving the relatively deprived and 
culturally diverse north and east of the city of Glasgow and its suburbs. The annual 
delivery rate is approximately 6000 births. Within the PRM, the neonatal unit is a 
tertiary referral centre, admitting around 500 babies per annum.  
  
The eligible population comprised mothers delivering a live singleton infant at any 
gestation within each specified 24-hour collection window. In order to achieve a 
random sample of the population delivering at the PRM while dealing with the 
practicalities of recruitment, the study was designed to run over two 20-week 
periods within a year, during which as many mothers as possible would be recruited 
during each fourth 24-hour period (00:01 to 24:00 hours). Collection of samples 
every day for a full year was impractical because of the need for informed, written 
consent and the involvement of only one investigator. Every fourth day avoided 
potential weekend variation in drinking alcohol.  
  
The study was delivered at point of care in sites including prenatal, labour ward, 
postnatal and neonatal unit in order to minimise study burden to delivering 
mothers and therefore optimise recruitment rates. Women were excluded if the 
infant was thought not to be likely to survive, or if they lacked capacity or if their 
state of mind meant that either that approaching them to discuss the study was not 
appropriate or informed consent was unable to be achieved. The midwives looking 
after the mothers guided the researcher with regards to the appropriateness and 
timing of approaching mothers, appreciating that delivery can be a sensitive time.  
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The design of the study was informed by a previous feasibility study undertaken in 
the same department by other members of the PRM research team and alluded to 
in the introduction(78). Additionally, we set out to explore the usefulness of 
assaying alcohol biomarkers in newborn dried blood spot cards. Routine newborn 
blood spot screening is undertaken between 96 and 120 hours of life (generally on 
day five of life) by the community midwives.  Once newborn screening has been 
carried out the cards are routinely stored indefinitely, unless there is specific 
parental request otherwise(144). Should alcohol biomarkers in dried blood spot 
cards correlate with meconium biomarkers and/or maternal alcohol history, this 
raises the potential usefulness of retrospective measurement of alcohol biomarkers 
in dried blood spot cards either as a diagnostic tool for children suspected to have 
FASD or for anonymised national population screening to assess PAE.    
  
2.3 Choice of biomarkers   
The advantages and disadvantages of different alcohol biomarkers measurable in 
the newborn have been fully described in the introduction, together with their 
diagnostic accuracy.  There are multiple FAEEs including around 20 variants. 
Different researchers have reported differing combinations of FAEEs in studies of 
PAE; our decision to use a total of four FAEEs including ethyl myristate, ethyl 
palmitate, ethyl oleate and ethyl stearate was for two reasons: pragmatic, to allow 
direct comparison with the feasibility study; and because Himes et al. found the 
sum of these four FAEEs to have better agreement with self-reported PAE than the 
sum of either all nine FAEEs, or the sum of seven FAEEs excluding ethyl laurate and 
myristate(78, 120).  
  
An appropriate cut-off value for a total of four FAEEs in infant meconium as a 
marker of regular prenatal alcohol consumption is a balance between sensitivity 
and specificity.  A cut off value of 600 ng/g has consistently been reported to have 
a sensitivity of 100%, but with a specificity varying from 13 - 98.4% using detailed 
maternal self-report as the standard(78, 111, 120, 121).  
  
EtG > 30 ng/g was reported by Himes et al. as superior to summated FAEEs in terms 
of agreement with self-reported alcohol consumption beyond 19 weeks’ gestation, 
so this was included in our analyses(120). Since the two biomarkers may be more 
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useful in combination, we chose to analyse both from the same meconium sample 
as in the feasibility study(145-147).   
  
As a pilot arm of this study, we sought to analyse newborn blood spot cards for 
PEth, with the aim of investigating the potential use of routinely collected and 
retained newborn blood spot cards as a retrospective measure of PAE. 
Measurement of PEth has not been previously carried out in blood spot cards 
collected in the UK infant population.  We sought REC permission to obtain blood 
spot cards additional to those obtained for routine newborn screening so as not to 
interfere with potential clinical use of routinely retained blood spot cards for 
retrospective infant testing for other conditions (e.g. cytomegalovirus 
exposure)(144).  
  
2.4 Funding  
Funding was obtained in summer 2014 by competitive application to the Yorkhill  
Children’s Charity (now Glasgow Children’s Hospital Charity) for a one-year Clinical 
Research Fellow post, commencing August 2015. Ideally, we would have sought two 
years’ funding, but at the time of application, YCC was only awarding one-year 
fellowships, with no guarantee of a second year’s funding.  A grant of £57,808 was 
awarded to cover a Clinical Research Fellow salary for one year, the costs of 
analysis of 750 meconium samples and blood spot cards and in addition University 
of Glasgow MD fees (one-year full time, two years part-time). 
 
During the twelve-month period prior to the start of the fellowship, I finalised the 
study protocol in conjunction with my supervisor and submitted it for approval by 
both Research Ethics Committee (REC) for the West of Scotland 3 and the Research 
and Development (R&D) department of NHS Greater Glasgow and Clyde. This 
enabled recruitment for the study to start within three weeks of the beginning of 
my fellowship and allowed recruitment to occur over the majority of one full 
calendar year. More details of my direct involvement in REC and R&D approval are 
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2.5 Research Ethics Committee Approval   
Following awarding of funding, REC approval was sought through the Integrated 
Research Application System (IRAS). I personally completed the IRAS form under 
supervision by my research supervisor Dr Mactier and prepared all of the 
accompanying documentation, including information leaflets and consent forms.  
  
As previously noted, a smaller, feasibility study of meconium biomarkers had 
previously been completed by a different members of my supervisor’s research 
team and included 253 mother and infant dyads within the same research centre: 
this feasibility study confirmed maternal willingness to take part in a study 
examining infant alcohol biomarkers and facilitated the IRAS application(78). 
Following completion of the IRAS application, together with my research supervisor 
I attended a West of Scotland REC 3 meeting on 28/05/2015. The REC declared 
initially that written informed consent should be obtained from all participants 
prior to delivery, but the practicalities of this decision troubled us. During 
subsequent discussion with the REC panel, we highlighted that this would a) make 
executing the study very difficult therefore limiting recruitment and probably 
making the study not reflective of the general population and b) (more 
importantly) seriously undermine the scientific validity of the study. Specifically, 
we were concerned that approaching women prior to delivery might result in 
mothers changing their pattern of alcohol consumption during pregnancy, as well as 
potentially discouraging those with significant alcohol consumption from taking 
part. We agreed to display posters in antenatal clinics advising prospective mothers 
of the study, emphasising the anonymity of the study, and pointing out that 
mothers-to-be had a 25% chance of being eligible for the study (collection periods 
every fourth day). REC approval was also obtained to allow collection of the first 
meconium sample prior to written consent, to ensure that a minimum number of 
samples would be missed. The acute nature of maternity services means that 
predicting labour and delivery is very difficult, and we wanted all eligible mothers 
to have the opportunity to participate in the study. Written information was 
provided antenatally to mothers and their partners both in poster format and 
information leaflets, which had been reviewed and approved by the REC. Lastly the 
researcher was not involved in clinical work, therefore any information given to the 
researcher regarding alcohol consumption during pregnancy would not be shared 
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with the clinical team. R&D approval was obtained via IRAS from NHS Greater 
Glasgow and Clyde and the study registered with the R&D department on 
05/08/2015.  
 
2.6 Study Aims and research questions as described in the research protocol:  
Aims:  
• To describe the pattern and prevalence of alcohol consumption by pregnant 
women in Glasgow during the second and third trimesters of pregnancy by 
assay of FAEEs and EtG in meconium.   
• To compare FAEEs and EtG measured in meconium with PEth measured from 
a dried blood spot collected along with routine blood spot screening as a 
marker of alcohol consumption in pregnancy.  
• To relate postnatally acquired data, including a confidential maternal 
interview and results of FAEE, EtG and PEth assays, to routinely collected 
antenatal information regarding maternal drinking in pregnancy.   
Research questions:  
• What are the levels of FAEEs and EtG in meconium samples from singleton 
term and preterm infants born in a single maternity hospital in Glasgow?  
• What are the relationships between high levels of FAEEs and EtG in infant 
meconium and maternal age, parity, smoking, ethnicity, and socioeconomic 
status?  
• What are the relationships between high levels of FAEEs and EtG in infant 
meconium and infant gestation, birth weight and head circumference?  
• What are the relationships between high levels of FAEEs and EtG in infant 
meconium and maternal alcohol intake during pregnancy as self-reported at 
booking and immediately post-delivery?  
• What are the levels of PEth in dried blood spot cards from singleton term 
and preterm infants born in a single maternity hospital in Glasgow?  
• What are the relationships between high levels of PEth in dried blood spot 
cards and maternal age, parity, smoking, ethnicity, and socio-economic 
status?  
• What are the relationships between high levels of PEth in dried blood spot 
cards and infant gestation, birth weight and head circumference?  
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• What are the relationships between high levels of PEth in dried blood spot 
cards and maternal alcohol intake during pregnancy as self-reported at 
booking and immediately post-delivery?  
• What is the relationship between levels of FAEEs and EtG in meconium and 
levels of PEth in dried blood spot cards in singleton term and preterm 
infants?  
  
2.7 Recruitment  
2.7.1 Preparation for recruitment  
During the period between obtaining REC and R&D approvals I met with hospital 
and community midwives to provide and discuss information in regard to the study 
protocol and day to day running of the study, including recruitment and sample 
collection. Folders providing detailed study information including a copy of the 
study protocol and consent forms were made available in each ward at PRM, 
including maternity assessment and the community midwifery base. Posters 
containing information about the study were displayed in clinical areas including 
labour ward, maternity assessment, and the postnatal wards.  These posters 
provided eligible mothers as well as clinicians with outline study information, 
where to find further information and research team contact information. 
(Appendix 1)  
  
Immediately prior to each study collection day the night team in the maternity 
assessment ward, labour ward, postnatal wards, and neonatal unit were contacted 
to ensure staff knew that a study day was scheduled the following day; this 
information was repeated at every change of shift during the 24-hour recruitment 
period and highlighted in the safety brief at each change of shift to ensure all 
members of staff on shift were aware. Pre-arranged study dates (every fourth 
calendar day) were made widely available.    
  
In total there were 71 study days - the first collection period was slightly shorter at 
19 weeks (second collection period 21 weeks in duration) due to closure of the 
clinical research facility laboratory during the Christmas period.   
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2.7.2 Study recruitment  
Antenatally:  
Potentially eligible mothers were approached after 35 weeks’ gestation, either in 
the maternity assessment unit, antenatal wards or antenatal clinics and offered an 
information leaflet detailing the study, noting that there was a one in four chance 
of them being eligible. (Appendix 1) This information leaflet had been approved by 
the REC. Additionally, I made personal contact with all mothers who were planned 
for induction of labour or elective caesarean section to provide verbal and written 
information about the study.  
  
Postnatally:  
Eligible mothers admitted in labour were provided with written information about 
the study by the admitting labour ward midwife as well as a yellow plastic bag to 
collect the baby’s first meconium-filled nappy in.  Subsequently, if contact was 
deemed appropriate by the attending midwife, I spoke to each mother in the 
labour ward. At this stage, mothers were provided with further study information 
and given the opportunity to ask questions about the study. The majority of eligible 
mothers were seen by me prior to delivery; a few others were first seen by myself 
in the postnatal wards.  I did not approach the few mothers without capacity to 
consent or where contact was not deemed appropriate. I sought to approach all 
eligible mothers within 24 hours of delivery (generally within a few hours) and to 
ask for consent to enrol them in the study. If a mother declined to participate and 
a soiled nappy had already been collected, this was discarded as per local clinical 
waste policy.  
  
Pending formal consent, any yellow plastic bags containing meconium soiled 
nappies were placed in a dedicated area in the sluice in the postnatal ward with a 
patient addressograph label attached. The ward sluices are free from natural light, 
ensuring that the samples were kept safely in the dark and in a clinical area. The 
reason for only taking written, informed consent after delivery was that it would 
be inappropriate to consent mothers in active labour. The consent process ensured 
that participating mothers had ample opportunity to ask questions about the study 
before consenting.  For those mothers for whom English was a second language, 
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foreign language interpreters or (in two cases) British sign language interpreters 
were used to obtain consent.   
  
After obtaining written consent, I administered a health questionnaire to each 
participating mother. This questionnaire included the gestation at which the 
mother found out she was pregnant (weeks), how many previous pregnancies and 
how many previous live births she had had, any medication taken in pregnancy and 
her smoking status. I also asked if any alcohol had been consumed during 
pregnancy.  If mothers reported alcohol consumption in pregnancy, they were 
asked more details including the timing of alcohol consumption and the type and 
amount of alcohol consumed; this was recorded using a calendar style method. 
Participants were encouraged to utilise telephones, diaries and, where relevant, 
social media to prompt recollection of timing of alcohol consumption.  Particular 
focus was made on special occasions such as birthdays and anniversaries to act as 
prompts with the aim of identifying in which trimester alcohol had been consumed. 
I also documented whether alcohol consumption was prior to or after knowledge of 
pregnancy.  
  
Maternal and infant medical notes were reviewed in order to obtain demographic 
information including parity, post code of residence, ethnicity, and documented 
alcohol intake at booking appointment. These demographic details were recorded 
on a clinical research file (CRF) (Appendix 2) and subsequently transcribed by me 
into an Excel spreadsheet, categorised to allow for statistical analysis.  
  
2.8. Collection, storage, and transportation of samples  
2.8.1 Meconium  
Meconium samples were either given directly to the researcher or placed in the 
designated area in the sluice (see above) to reduce the likelihood of accidental 
disposal.  Meconium samples were subsequently placed in a plain universal 
container directly from the nappy; no apparatus was utilised in order to avoid 
contamination.  Care was taken to avoid any meconium which had come into 
contact with baby nappy wipes as some contain alcohol. In theory meconium 
contaminated with bacteria could result in metabolism of alcohol in baby wipes to 
produce FAEEs.  Meconium samples were labelled with a study number and 
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maternal date of birth; a handwritten list matching study number to maternal CHI 
was stored securely in a locked office.  
  
Meconium samples were taken to the laboratory within the Clinical Research 
Facility at Glasgow Royal Infirmary (adjacent to PRM) up to four times per 
collection day, depending on the number of samples.  The meconium samples were 
then frozen at -40°C in a designated freezer. If samples were obtained out of hours 
(i.e., between 17:00 and 08:00 on weekdays and all day at weekends) they were 
frozen at -20oC at the biochemistry department based at Glasgow Royal Infirmary 
and transferred to the Clinical Research Facility freezer during the next working 
day. The longest time interval between collecting any meconium sample and it 
being frozen would have been between my final evening check at 23:00 and 
subsequent early morning round at 08:00 (9 hours). During the midweek collection 
days most samples reached the -40OC freezer within 4 hours.  
  
The exact duration of time that each meconium sample was stored for prior to 
freezing was not documented – in hindsight this was a minor weakness of the 
protocol. However, had sample times been documented, these would have 
reflected the time the nappy was changed and, in many cases, not the time the 
infant passed the meconium. Thus, documenting sample collection time would 
have been of limited value.  Meconium samples were shipped to the University of 
Padova, Italy on dry ice with temperature monitoring to ensure that the 
temperature remained less than -40oC during transit.  The samples subsequently 
underwent LC-MS/MS for the measurement of FAEEs and EtG (see laboratory 
analyses below).  
  
2.8.2 Blood spot cards  
When a mother consented to participate in the study, a blood spot card labelled 
with the study number and maternal date of birth was attached to the maternal 
handheld notes which were subsequently taken home by the mothers and used by 
the community midwives. Specifically, this blood spot card was attached to the 
page in the handheld notes where consent is documented for routine newborn 
blood spot screening, ensuring that it was visible to the midwife at the time of 
taking consent for newborn screening. Blood spot cards were only issued for 
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participants who had provided written consent; mothers had the right subsequently 
to withdraw or to refuse consent at the time of newborn blood spot sampling. On 
day five, if mothers had consented to the study and were still in agreement, the 
community midwife tried to obtain an additional blood spot on the second card 
following routine newborn blood spot screen. This second blood spot card was 
dependent upon the baby continuing to bleed after the routine blood spot screen. 
Further heel stick was not performed. Routine demographic data collected at this 
time were transcribed to the study blood spot card including method of feeding 
and if the infant had undergone treatment for jaundice or had a blood transfusion. 
The blood spot card was dried in room air and collected at PRM, either deposited in 
a designated box at PRM or posted back.   The samples were kept out of direct 
sunlight and vacuum packed to reduce exposure to humidity prior to being frozen 
at -40°. Unfilled blood spot cards were returned with information regarding 
whether the mother had declined consent or whether the midwife had been unable 
to obtain sufficient blood.  
  
It is common practice for staff to utilise alcohol gel and then apply gloves prior to 
taking a blood spot card sample. Use of an alcohol wipe to cleanse the heel prior to 
obtaining a heel prick sample is not mandated.  If an alcohol wipe is utilised to 
cleanse the area it should be allowed to dry and therefore the alcohol evaporate 
prior to the sample being obtained. The study blood sample was obtained after the 
routine blood spot sample and we were measuring a metabolite of alcohol (PEth) 
rather than alcohol per se. For all these reasons, contamination of the study blood 
spot card with alcohol was considered extremely unlikely. Since the study aim was 
to see if routinely obtained blood spot cards could be utilised retrospectively to 
determine PAE, while there may have been more caution around the use of alcohol 
hand gel, changing sampling practice was not appropriate. 
   
Blood spot cards were shipped on dry ice in a thermally regulated package at -40° 
to the University of Padua (Universita degli Studi di Padova) in Italy together with 
meconium samples. They were subsequently analysed there for the presence of 
PEth. Blood spot cards were linked anonymously via the study number to meconium 
samples to enable comparison of results from different samples from the same 
baby.  
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2.9. Demographic Data  
One of the study aims was to identify if there were demographic differences in the 
population presenting with high alcohol biomarkers compared to low or absent 
alcohol biomarkers. The previously described feasibility study with a smaller study 
population suggested that PAE may be more common in more affluent mothers(78). 
We were aware of a common assumption that poorer mothers are more likely to 
misuse alcohol, but this is not evidence based.  
  
It was intended to compare mothers recruited into the study with the entire 
population delivering at PRM during the study period in order to ensure that the 
recruited population was truly representative. An anonymised download of data 
from the Pregnancy and NewBorn Screening (PNBS) database via the Safehaven was 
planned, to determine overall population demographic details for comparison with 
the recruited study population. Unfortunately, this data download proved to be 
uninterpretable on a pilot download, therefore a further download was not carried 
out. Scottish Birth Record was screened to identify eligible patients who had 
delivered in each 24-hour period and could be approached by the researcher. Basic 
demographic information including the community health index (CHI) number (from 
which age can be obtained), postcode and mode of delivery were used to identify 
eligible mothers; these data allowed identification of which ward mothers were 
being cared for in, and prioritisation of those mothers who had delivered vaginally 
(predicted earlier hospital discharge).  These basic, anonymised data were entered 
into a secure spreadsheet on the NHS server and compared between mothers who 
participated in the study and those who declined to participate, to ensure that the 
mothers who declined to participate were not different from the population as a 
whole. A more comprehensive comparison would have been carried out as per REC 
approval had the planned data download from PNBS been successful.  
  
When a mother consented to inclusion in the study, I reviewed both maternal and 
baby clinical notes in order to obtain demographic information including maternal 
age, parity, ethnicity, postcode of residence and smoking status at booking, 
together with baby’s birth weight, gestation, APGAR scores and occipital frontal 
circumference (OFC). Postcode was converted to an SIMD16 score to give a measure 
of socioeconomic deprivation(148). Parity was documented based on self-report 
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and was described in a single digit as the number of previous live birth(s) and/or 
stillborn children delivered after 24 weeks’ gestation. Maternal ethnicity was 
recorded as had been reported by the mother at booking and documented in the 
maternal hand-held notes. Thus, ethnicity was self-identified. 
  
2.9.1 Measure of socioeconomic deprivation    
The DEPCAT socioeconomic score based on postcode of residence had been used in 
the feasibility study, but I chose to use a more recent measure of social deprivation 
for the current study, Scottish Index of Multiple Deprivation (SIMD)(148). SIMD was 
originally published by the Scottish government in 2004 and the most up to date 
version published in 2016 (SIMD16)(149).  SIMD is a measure of deprivation across 
Scotland based on postcode. In assigning a score, SIMD considers more variables 
than DEPCAT, including employment, income, crime, housing, health, education 
and access to transport links and healthcare within a given postcode.  These seven 
categories are further subdivided with 38 variables which are combined to provide 
a SIMD score between 1 (most deprived) and 6976 (least deprived).  Individuals who 
do not have a postcode, e.g., homeless, prisoners and travelling communities are 
given a generic postcode to generate a deprivation scale estimate which is 
therefore of limited value.  An additional problem is that new build houses which 
have not been issued a postcode will not register a SIMD score(149).    
  
Demographic data were collected onto CRFs and then transcribed to the 
anonymised master Excel spreadsheet.  The original CRFs were stored in a locked 
cabinet in a locked office at PRM. 
 
2.10 Laboratory analyses  
2.10.1 FAEEs and EtG in meconium  
To ensure stability, samples were transferred in a frozen state to the University of 
Padua in Italy for analysis(147).  LC-MS/MS was carried out for the measurement of 
FAEEs (ethyl myristate, ethyl palmitate, ethyl oleate and ethyl stearate) and EtG.  
200 mg of meconium was sonicated for 15 minutes with 20 ng EtG-d5 and 200 ng of 
FAEE d-5.  The supernatant was added to an aminopropyl solid-phase extraction 
cartridge, preconditioned with 2 ml methanol, water and acetonitrile (ACN).  FAEEs 
were eluted with 2 ml hexane and EtG elution carried out with 2 ml water.  The 
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two mixtures were dried using nitrogen stream and recovered with 50 µl of ACN 
(FAEEs) and 50 µl methanol (EtG).  FAEEs were detected following separation using 
a C8 reversed-phase column.  A C18 reversed-phase column was used in isocratic 
mode for EtG detection.  Acquisition was in multiple reactions monitoring for all 
the analytes in positive mode for FAEEs and negative mode for EtG.  Lower limit of 
quantification (LOQ) values were 10-15 ng/g for FAEEs and 10 ng/g for EtG.  
  
2.10.2 PEth in dried blood spot cards  
PEth and the internal standard (pentadeuterated PEth) were dissolved in 
dichloromethane at a concentration of 1 mg/ml.  Working solutions were prepared 
at a concentration of 20 µg/ml with methanol. All standard and working solutions 
when not in use were kept at -20°C. From each dried blood spot card, a blood spot 
(30 µL) was removed by a manual punch (5 mm diameter) and placed in methanol 
for extraction (2 ml). After an hour, the solvent was transferred and evaporated to 
dryness in a nitrogen stream. The dried extract was dissolved with isopropanol (100 
µl) and after stirring transferred to the vial for the LC-MS/MS analysis. The LC-ESI-
MS/MS system consisted of an Acquity UPLC chromatograph coupled to a Xevo TQ-S 
Micro Mass Spectrometer (Waters). 5 µl of the extracts were injected on a Waters - 
Acquity BEH C8 column (2.1 x 50 mm, 1.7 µm) with a flow of 400 µl/min at a 
temperature of 55 °C. Gradient elution was performed with 10 mM ammonium 
acetate buffer (0.5% formic acid) and 2-propanol (10% tetrahydrofuran).  
  
The mass spectrometer was operated in electrospray ionization in negative ion 
mode. The desolvation temperature was set at 350 °C, the gas nebulizer flow at 
600 l/min, the ionization potential was 3.5 kV. Calibration curves were prepared on 
DBS by spotting 30 µl of blank blood, obtained from an alcohol abstinent subject, 
fortified at a concentration of 20, 40,100, 400, 800 and 1600 ng/ml of each PEth 
homologue. Quality controls are routinely added including blanks and samples at 
known concentrations; if the highest concentration was higher than that of controls 
they were diluted and then reanalysed. The laboratory undergoes bi-annual 
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2.11 Statistical analyses  
Data were collected from patient questionnaires and clinical notes as appropriate and 
entered into a CRF (Appendix 2); data were subsequently transcribed to an Excel 
spreadsheet. SIMD16 scores were calculated from postcodes as described previously. 
Patient data were then merged with laboratory results, matched by study number. Once 
all data entries had been double-checked the spreadsheet was locked. Using Excel 2016, I 
extracted descriptive data and calculated mean, median, standard deviation, range, 
percentages as relevant in order to construct data tables. The completed tables were 
examined to identify potential differences between variables.   
 
For those demographics and/or laboratory results which appeared to differ, statistical 
analysis was undertaken in collaboration with Dr. David Young, statistician. To avoid types 
1 errors, statistical analysis was not undertaken where no obvious difference was 
observed. Analyses were carried out utilising Mini-tab (version 18). Categorical variables, 
e.g., SIMD16 quintiles, were compared using a CHI square test. For those categories with 
two relatable observations e.g., smoking status (yes or no) and ethnicity (White British vs 
non-white British) a paired t-test was undertaken. Pearson’s co-efficient was used to 
investigate relationships between (non-linear) biomarkers.  
 
I personally calculated the sensitivities, specificities, positive and negative predictive 
values of each of the infant biomarkers (FAEE, EtG and PEth). I used as the gold standard 
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3.0 Results  
3.1 Recruitment  
The study ran from 12/08/2015 to 22/12/2015 and from 20/01/2016 to 16/06/2016 
inclusive. This gave a total of 71 collection days.  
1045 infants were born on these 71 study days (Figure 3.1) Of the seven ineligible 
singleton births, two babies were born at home, one baby was transferred out for 
specialist neonatal care, one baby died within the first seven days of life, one baby 
was placed for adoption, one mother did not have capacity to consent, and one 
mother was too unwell to approach for consent.  
I approached 908 (89.5%) mothers of the 1014 eligible singleton infants, of whom 
840 (92.5%) agreed to participate.  
Sample collection and return is illustrated in Figure 3.2. In total 740 meconium 
samples were collected, and 668 dried blood spot cards were returned. A few 
meconium samples could not be analysed and 11.6% of the dried blood spot cards 
either had no blood or an insufficient sample. A full set of alcohol questionnaire, 
analysable meconium and a well filled dried blood spot card was collected from 
445 mother/infant dyads.  
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 3.2 Maternal demographics  
The demographics of recruited mothers are presented in Table 3.1. Demographic 
data are presented separately for those mothers who agreed to participate and 
who provided at least one infant sample (meconium and/or dried blood spot card) 
and for those mothers from whose infants no samples were obtained (potential 
tacit refusal). A blank dried blood spot card which was unfilled or incomplete 
because the baby did not bleed sufficiently well counted as sample returned. To 
ensure a representative population had been recruited limited anonymised data 
were collected from the Scottish Birth Record for those mothers who declined to 
take part. As described in the Methods chapter, these data were of necessity fewer 
than originally intended.  
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(years) mean  
(SD)  
N=840  61  813  27  740  100  
29.8 (5.7)  29  29.8 (5.6)  30.5 (6.3)  29.8 (5.6)  29.5 (5.9)  
range  16 – 50.3  16 – 39  16 – 50.3  18.9 – 42.7  16.0 – 50.3  18.9 – 45.4  
         
Maternal 
BMI (kg/m2)  
Median  
(IQR)  
N=822    795  27  724  98  
 25.8   
(22.9 –  
30.3)  
  26.0   
(22.8 –  
30.3)  
25.0   
(23.2 –  
29.2)  
26.0   
(22.8 –  
20.2)  
25.6   
(23.3 –  
30.1)  
range  15.2 – 59    15.2 – 59  18 – 52.5  15.2 – 59  17.9 – 52.5  




N=831  60  804  27  731  100  
3 (1 – 6)  3 (1-10)  3 (1 – 6)  3 (1 – 5)   3 (1 – 6)  3 (1 – 7)   
range  1 – 10  1 – 10  1 – 10  1 – 10  1 – 10  1 – 10  
         
Ethnicity  
(% White  
British)  
N=803    779  24  709  94  
80.3%    80.6%  70.8%  80.3%  80.9%  
         
Parous mums  
(%)  
  
N=822    796  26  727  95  
56.3%    56.4%  53.8%  55.8%   61.3%  
Mode of delivery 
(% vaginal)   
N=839  60  812  27  739  100  
61.5%  60%  61.5%  63%  
  
61.3%  63%  
Table 3.1: Maternal demographics according to sample collection  
  
Maternal age ranged from 16 to 50.3 years. For those mothers who were 
approached for consent for the study and agreed to participate (n = 840), mean age 
on the day of delivery was 29.8 (+/- SD 5.7) years. There was no difference in age 
between those eligible mothers who were approached for consent and either 
agreed or declined to participate, or between those mothers who consented to the 
study and from whose infants a sample of meconium and/or dried blood spot card 
was obtained, and those mothers who consented to the study but who did not 
supply either a meconium sample or dried blood spot card (Table 3.1).  
  
Body mass index (BMI) had been documented for 822/840 (97.9%) mothers recruited 
to the study and ranged from 15.2 to 59 kg/m2. Data were slightly skewed; median 
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BMI was 25.8 kg/m2 (IQR 22.9 to 30.3) and mean BMI was 27.2 kg/m2 (SD 6.3). BMI 
was so poorly documented in the Scottish Birth Record that it could not have been 
investigated for those mothers who declined to participate.  
  
SIMD 16 scores calculated from maternal postcode ranged from 1 to 6976 and were 
ranked into deciles. The lowest decile represents the areas of most socio-economic 
deprivation.  SIMD 16 score was available for 831 of 840 women recruited to the 
study (98.9%). Not all postcodes were able to be translated to SIMD 16 scores due 
either to not having been written in the correct format (n=3) or data missing (n=1) 
or not having a corresponding SIMD 16 score (n=5). The latter scenario applied 
particularly to new build properties for which the postcode was not present at time 
of formulation of the SIMD scoring system.  The population of recruited mothers 
was highly skewed towards the more deprived postcodes with 247 (29.7%) residing 
in areas with SIMD 16 scores in the most deprived decile, consistent with the 
maternity hospital location and catchment area. (Figure 3.3) The median SIMD 
decile was 3 (IQR 1 to 6).   
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Socioeconomic status as described by SIMD 16 did not vary between mothers who 
consented or declined, or between mothers who supplied a sample compared to 
those that did not.   
  
Ethnicity data (self-reported) were available for 803 of the 840 women recruited to 
the study (Tables 3.1 and 3.2). Mothers who provided at least one sample tended 
towards an ethnicity of white British compared to mothers who provided no 
samples 80.6 vs 70.8%; this difference was not significant (p=0.23).  688 (81.2%) 
mothers had their first language documented at booking, of whom 591 (86%) were 
recorded as having English as a first language.  
Ethnicity Number of Mothers 
African/African Caribbean 35 
South Asia 36 
South East Asia (China, Malaysia, Thailand) 23 
Other non-European (Middle east, South America, North Africa) 19 
Southern and Other European (Poland, Russia, Sardinia, Greece) 37 
White British 645 
Northern European 8 
Mixed 0 
Other Ethnicity 0 
Total 803 
Table 3.2: Self-declared maternal ethnicity  
  
Previous pregnancies were documented from the handheld maternity notes. 270 
(32.4%) of the 809 mothers recruited to the study for whom data were available 
had previously had at least one fetal loss before 24 weeks’ gestation, of whom 81 
(10% of recruited mothers) were documented as having had more than one fetal 
loss. 251/809 (31%) mothers stated in the confidential postnatal health interview 
that they were pregnant for the first time. 463/822 mothers had previously 
delivered a baby after 24 weeks’ gestation or a live baby prior to 24 weeks’ 
gestation (56.3%). For the purposes of this thesis, I defined only these 463 mothers 
as “parous”. While a previous early fetal loss also confers the status of “parous”, 
early fetal loss data were less complete and potentially under-reported. For the 
purposes of comparing biomarkers, women were divided into two group – 463 
“parous” mums as described above and 359 “first time mums” who had not 
previously delivered such a baby.  




Mode of delivery was documented for 839 mothers: 407 had a spontaneous vertex 
delivery (SVD), 109 had an assisted vaginal delivery and 323 were delivered by 
caesarean section. Of the caesarean deliveries, 143 were categorised as emergency 
and 180 as elective caesarean section. For those mothers who were approached for 
consent and declined, mode of delivery was ascertained from the Scottish Birth 
Record as part of screening and recruitment prioritisation. Theoretically variation 
in mode of delivery may have affected recruitment, due to earlier discharge from 
the maternity unit and thus less opportunity to obtain study consent from mothers 
who delivered vaginally. There was no difference in the mode of delivery of 
mothers who participated in the study compared to those who declined to 
participate in the study (Table 3.3). Mode of delivery is simplified in Table 3.1 into 
vaginal or caesarean birth for presentation in relation to sample collection.  
  
Mode of Delivery  Recruited  Percentage 
(%)  
Declined  Percentage 
(%)  
Total (number)  839     60     
Spontaneous  
Vertex Delivery  
(SVD)  
407  48.5  30  50  
Ventouse  55  6.6  3  5  
Forceps  54  6.4  3  5  
Emergency 
caesarean section  
143  17.0  7  11.7  
Elective caesarean 
section  
180  21.5  14  23.3  
Uncategorised 
caesarean section  
0  0  3  5  
Table 3.3: Mode of delivery   
  
3.3  Infant demographics  
Of the 840 infants recruited to the study, 421 (50.1%) were male (Table 3.4). 
Gestation was documented for 837 of 840 babies recruited to the study and ranged 
from 28 to 42 weeks with a mean gestation of 38.9 (SD 1.7) weeks and a median of 
39 weeks. 53 (6.3%) babies were of less than 37 weeks’ gestation at delivery.  
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Infant sex (% 
male)  
N=840  813  27  740  100  
50.1%  50.3%  44.4%  51.1%  43%  




837  810  27  737  100  
38.9 (1.7)  38.9 (1.7)  38.6 (1.7)  38.9 (1.6)  38.9 (1.8)  
range  28 – 42  28 – 42  33 – 41  30 – 42  28 – 41  
       
Birthweight  
(g)  
mean (SD)  
838  811  27  738  100  
3367 (526)  3374 (529)  3162 (401)  3373 (525)  3330 (538)  
range  960 – 4905  960 – 4905  2086 – 3702  1320 – 4950  960 – 4450  
       
OFC (cm) 
Mean (SD)  
825  801  24  728  97  
34.6 (1.5)  34.6 (1.5)  34.2 (1.2)  34.6 (1.4)  34.5 (1.9)  
Range  24.8 – 41.5  24.8 – 41.5  31.2 – 35.6  29.5 – 41.2  24.8 – 41.5  
       
APGAR score 
mean (SD)  
829  802  27  731  98  
9 (1.3)  9 (1.3)  9 (1.3)  9 (1.3)  9 (1.2)  
range  0 – 10  0 – 10  4 – 9  0 – 10  1 – 10  
Table 3.4: Infant demographics in relation to sample collection.  
  
Birth weight was documented in the Scottish Birth Record for all but two babies 
recruited to the study and ranged from 960 to 4905 g with a mean of 3367g (SD 
526g). 41 babies had a birth weight of less than 2500g (4.9%). Babies from whom no 
samples were obtained tended to be a little lighter at birth compared to those 
from whom at least one sample was obtained (mean 3162 vs 3374 g). Consistent 
with slightly lower birth weight, head size, measured as occipito-frontal 
circumference (OFC) tended to be less in those infants whose mothers consented to 
the study but from whom no samples were obtained (34.2 vs  
34.6 cm).  
  
Birth was more common between 09:00 and 12:00, reflective in part of the timing 
of elective caesarean sections (Figure 3.4).   




Figure 3.4: Time of birth of recruited infants.  
  
3.4 Maternal smoking and alcohol consumption  
As part of the confidential postnatal health questionnaire, smoking status 
(continued to smoke in pregnancy, stopped smoking in pregnancy or never smoked) 
was asked directly by the researcher of 828/840 mothers recruited to the study. 
223 mothers (26.9%) declared smoking prior to pregnancy, of whom 145 (65%) 
continued to smoke in pregnancy. A further two mothers started smoking in this 
pregnancy. Thus 17.8% of all recruited mothers for whom data were available 
















































































Time of Birth 
     
  
82 





















Smoked prior to 
pregnancy  
N=828  802  26  731  97  
26.9%  26.8%  30.8%  26.8%  27.8%  
       
Smoked during 
pregnancy  
N=828  802  26  731  97  
17.8%  17.6%  23.1%  17.8%  17.5%  
Stopped smoking 
in pregnancy  
N=828  802  26  731  97  
9.4%  9.5%  7.7%  9.2%  11.3%  
Never smoked  N=828  802  26  731  97  
72.8%  72.9%  69.2%  73.1%  71.1%  
       
CO level mean 
(SD) (ppm)  
N=621  601  20  549  72  
2.5 (3.7)  2.5 (3.7)  2.9 (4.2)  2.5 (3.6)  2.8 (4.2)  
range  0 – 25  0 – 25  0 – 16  0 – 22   0 – 25  
% > 5ppm  12.7  12.6  15  12.8  12.5  
       
Ever drank prior 
to pregnancy  
N=828  798  26  727  97  
80.6%  80.3%  84.6%  80.7%  78.4%  
       
Drank prior to 
knowledge of 
pregnancy  
N=828  779  22  713  92  
30.6%  31.6%  23.1%  32.4%  22.8%  
       
Self-reported 
alcohol > 20 
weeks’ gestation  
N=827  801  26  730  97  
13.8%  13.6%  19.2%  13.2%  18.6%  
       
No alcohol in 
pregnancy  
N=828  801  26  730  97  
53.7%  53.8%  53.8%  53.6%  55.7%  
Table 3.5: Self-declared maternal smoking and alcohol consumption in relation to 
sample collection. 
 
Smoking status was incompletely documented in the maternal handheld record and 
very poorly documented in the Scottish Birth Record. Despite being a universal 
screening test for smoking, carbon monoxide level as ascertained by a breath test 
had been documented at the booking visit for only 621 (73.9%) of the 840 recruited 
women. 93 (15%) mothers had a CO level of greater than or equal to 4 ppm (trigger 
for referral to the smoking cessation services). Of the women who declared at the 
postnatal interview never to have smoked, 93/524 (17.7%) of those tested returned 
a positive CO test (>4 ppm).   




Overall, at least one sample was obtained from the infant for 813/840 recruited 
mothers (96.7%) although not all blood spot cards had sufficient blood for analysis.  
141/147 (95.9%) mothers who smoked in pregnancy provided at least one of a 
meconium sample and/or a dried blood spot card compared to 661/668 (99%) 
mothers who either never smoked or who gave up smoking in pregnancy, this 
difference was significant (p=0.006).  In terms of meconium samples alone, 
130/147 (88.4%) of mothers who smoked in pregnancy provided a sample from their 
infant, compared to 601/681 (88.3%) of mothers who did not smoke in pregnancy.  
  
Compared to those mothers from whose infants at least one sample was obtained, 
a higher proportion of mothers who did not provide either a meconium sample or 
dried blood spot card reported smoking prior to pregnancy (30.8 vs 26.8%) or 
smoking during pregnancy (23.1 vs 17.6%). (Table 3.5) These differences were not 
however significant (p=0.65).  
  
827 women were asked during the confidential postnatal health questionnaire if 
they had consumed any alcohol during pregnancy (Table 3.5).  443 (53.6%) mothers 
stated that they had never consumed alcohol in pregnancy. Of the 384 mothers 
who reported consuming alcohol at any point in pregnancy, 252 (65.6%) stated that 
they only drank prior to knowing that they were pregnant. 114 (13.8%) of all 
recruited mothers who completed the questionnaire) reported drinking alcohol 
beyond 20 weeks of gestation of whom three reported one or more episode of 
binge drinking (i.e. five or more units of alcohol on one occasion). Fewer mothers 
reported drinking alcohol in mid-pregnancy. (Figures 3.5 and 3.6)   
  




Figure 3.5 Percentage of mothers reporting any alcohol intake in relation to stage 
of pregnancy.  
 
Women who self-reported any alcohol consumption in pregnancy (n=384) were 
more likely to identify as white British and to have smoked in pregnancy compared 
to those women who self-reported no alcohol consumption in pregnancy (n=443), 
(p= <0.0001). Women who self-reported alcohol consumption in pregnancy beyond 
20 weeks’ gestation were more likely to be aged > 35 years (p = 0.0004) and were 
also more likely to identify as white British compared to those mothers who did not 
report alcohol consumption in pregnancy after 20 weeks’ gestation (p <0.05) (Table  
3.6).  
  
Babies born to mothers who declared alcohol consumption after 20 weeks’ 
gestation had a mean weight of 3470 g compared to 3352 g (p=0.032); this was not 
explained either by gestation or by maternal BMI. Heavier birthweight was not 
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Table 3.6 Maternal self-report of alcohol consumption beyond twenty weeks’ 
gestation in comparison to maternal and infant demographics  
* self-report of alcohol consumption available for 827 mothers  
+ P=<0.05  






alcohol in  













Did not drink 







N=840  384  443  114  713  
29.8 (5.7)  29.5 (5.8)  30 (5.5)  31.3 (5.7)  29.5 (5.6)  
range  16 – 50.3  16 - 45.4  17 - 50.3  16 – 45.4  16.1 – 50.3  
% aged > 35 years  19.5  20.6  18.3  31.6+  17.4+  




N=822  380  429  112  697  
25.8  
(22.9 – 30.3)  
27.0  
(16 - 30.3)  
26.2  
(23 - 30.2)  
25.4  
(23 – 29.8)  
25.8  
(22.8 – 30.3)  
range  (15.2 – 59)  (22.8 - 53)  (15.2 - 59)  (19.1 – 53)  (15.2 – 59)  
        
SMID decile 
median (IQR)  
N=831  379  440  110  709  
3 (1 – 6)  4 (1 - 7)  3 (1 - 6)  5 (2 - 8)  4 (1 – 6)  
range  1 – 10  1 - 10  1 - 10  1 – 10  1 – 10  
        
Ethnicity  
(% White British)  
N=803  370  423  107  686  
80.3%  90.5%+  71.6%+  91.6%+  79.7%+  
       
Smoked during 
pregnancy  
N=828  383  442  113  712  
17.8%  20.1  15.8  13.3  18.5  
        
Parous mums  
(%)  
N=822  375  435  111  699  
56.3%  54.1%  57.7%  54.1%  56.8%  
Mode of delivery  
(% vaginal)   
N=839  383  443  114  712  
61.5%  62.9%  60.3%  60.5%  61.7%  
        
Infant sex  
(% male)  
N=840  384  443  114  713  
50.1%  50.8%  49.9%  48.2%  50.6%  
Gestation (weeks) 
mean (SD)  
N=837  382  442  113  711  
38.9 (1.7)  38.9 (1.5)  38.9 (1.8)  39 (1.3)  38.9 (1.7)  
range  28 – 42  32 - 41 28 - 42  34 – 41  28 – 42  
Birthweight (g) 
mean (SD)  
N=838 N=383 442  113  712  
3367 (526) 3369 (511) 3368 (538)  3470 (474)+  3352 (532)+ 
range  960 – 4905 1774-4672 3075 - 3705  2235 – 4675  960 – 4905  
OFC (cm)  
Mean (SD)  
N=825 375 438  111  702  
34.6 (1.5) 34.7 (1.5) 34.6 (1.5)  34.7 (1.5)  34.6 (1.5)  
Range  24.8 – 41.5 30.4 – 41.5 24.8-39  30.5 – 41.2  24.8 – 41.5  
APGAR score 
mean (SD)  
N=829 381 436  112  705  
9 (1.3) 9 (1.2) 9 (1.3)  9 (1.3)  8.6 (1.5)  
range  0 – 10  1 - 10  0-10  1 – 9  0 – 10  
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3.5 Infant biomarkers  
3.5.1 Analysis of Meconium for Fatty Acid Ethyl Esters (FAEE)  
740 meconium samples were sent for analysis of both fatty acid ethyl ester (FAEE) 
and ethyl glucuronide (EtG) concentrations, of which 712 meconium samples were 
successfully analysed for ethyl-myristate, ethyl palmitate, ethyl oleate and ethyl 
stearate as well as EtG. The concentrations of each of the FAEE metabolites were 
summed, to give total FAEEs (ng/g). (Table 3.7)  
  
  Fatty acid ethyl ester concentrations (ng/g)  
  Ethylmyristate  Ethylpalmitate  Ethyloleate  Ethylstearate  Total of 
4 FAEEs  
Min  3.6  5.9  7.3  2.4  22.2  
Max  2384.0  2166.2  2683.4  1266.6  7549.8  
Median  120.5  121.9  139.7  85.2  533.9  
Interquartile 
(25th)  
57.5  57.7  66.2  34  271.6  
Interquartile 
(75th)  
204.5  209.9  241.6  161.2  773.6  
Mean (SD)  
162.4 (211)  166.2 (193)  
190.4 
(237)  
124 (135)  
642.8 
(669)  
Table 3.7 Individual and total fatty acid ethyl esters (FAEEs) in meconium samples.  
  
Every meconium sample yielded a positive reading for FAEEs with the total 
concentration of FAEEs ranging from 22.2 to 7549.8 ng/g. Using a cut off value of 
≥600 ng/g total FAEEs, 282 (39.6%) meconium samples were positive, and 430 
(60.4%) samples were negative for FAEEs (Table 3.8). Of the positive meconium 
samples, 21 (2.9% of the samples analysed, 2.5% of all recruited mothers) yielded a 
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FAEEs   




FAEEs   






(years) mean (SD)  
N=712  282  430    
29.8 (5.6)  30.1 (5.3)  29.7 (5.8)    
range  16 – 50.3  16.0 – 43.6  16.1 – 50.3    
% >35 years  19.5  19.9  19.3  P=0.855  
  
Maternal BMI  
(kg/m2) median 
(IQR)  
N=696  274  422    
25.7   
(22.8 – 30.1)  
25.6   
(23 – 30.6)  
26.9   
(22.5 – 30)  
  
range  15.2 – 59  15.2 – 50.4  16.0 – 59  p=0.360  
  
SIMD decile 
median (IQR)  
N=704  280  424    
3 (1 – 6)  3 (1 – 7)  3 (1 – 6)    
range  1 – 10   1 – 10   1 – 10   P=0.387  
  
Ethnicity  
(% White  
British)  
N=682  276  406    




N=703  279  424    
17.9%  14.7%  20%  P=0.071  
  
Parous mums  
(%)  
N=699  280  419    
55.8%  57.9%  54.4%  P=0.368  
Mode of delivery  
(% vaginal)   
N=711  282  429    
61%  61.7%  60.6%    
  
Infant sex   
(% male)  
N=712  282  430    
51.3%  51.4%  51.2%    
Gestation 
(weeks)  mean 
(SD)  
N=709  282  427    
38.9 (1.6)  39 (1.5)  38.8 (1.7)    
range  30 – 42  30 – 42  31 – 40    
Birthweight (g) 
mean (SD)  
N=710  282  428    
3373 (526)  3425 (523)+  3331 (525)+ P=0.032+  
range  1320 – 4905  1600 – 4886  1320 – 4905   
OFC (cm) Mean 
(SD)  
N=700  276  424   
34.6 (1.4)  34.7 (1.4)  34.6 (1.5)   
Range  29.5 – 41.2  30.4 – 38.0  29.5 – 41.2   
APGAR score 
mean (SD)  
N=703  278  425   
8.6 (1.2)  9 (1.2)  8.6 (1.3)   
range  0 – 10  1 – 10  0 – 10   
Table 3.8 Maternal and infant demographics in relation to meconium sample 
positive or negative for FAEEs.  
 
There was no relationship between maternal age, BMI, SIMD score, parity or 
ethnicity and the likelihood of the infant’s meconium being either negative or 
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positive for FAEEs. Within the 20 mothers whose infant’s meconium sample yielded 
a total FAEE concentration of >2000 ng/g and for whom SIMD was available, there 
was a slight preponderance of postcodes in SIMD16 deciles 2 and 4, but numbers 
were too small to make meaningful statistical comparison.   
  
 
Figure :3.6 Socioeconomic profile in relation to meconium sample being positive for 
FAEEs.  
  
Mothers tended to have been less likely to smoke during pregnancy within the 
group whose infant’s meconium was positive for FAEEs, compared to the group 
whose infant’s meconium contained <600 ng/g FAEEs (14 vs 20%, p=0.071). Among 
infants of the 126 mothers who declared smoking during pregnancy total FAEE 
concentration in meconium was >600 ng/g in 32.5%. By comparison, 23/63 (36.5%) 
meconium samples from infants whose mothers reported stopping smoking in 
pregnancy were positive for FAEEs, compared to 215/514 (41.8%) for infants of 
women who had never smoked. This difference was not significant.   
  
The likelihood of infant meconium being positive for FAEEs was not related to sex 
or gestation, but mean birth weight was greater for those infants whose meconium 























Recruited population All meconium samples resulted 
FAEE ≥600ng/g FAEE ≥2000ng/g 
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infants with a negative meconium sample (P=0.032).  Mean OFC did not however 
differ between these two groups. 
 
Self-reported alcohol consumption as determined by confidential interview after 
delivery could be linked with 702 meconium samples. When infant meconium was 
positive for FAEEs, as defined by a concentration of ≥600 ng/g, 41/280 (14.5 %) 
mothers had reported alcohol consumption later than 20 weeks of pregnancy.  
When the concentration of FAEEs in infant meconium was <600 ng/g, 54/422 (13%) 
mothers had reported alcohol consumption after 20 weeks’ gestation, this 
difference did not reach significance. Thus, maternal self-report of any alcohol 
consumption in later pregnancy did not predict an infant meconium total FAEE 
concentration of >600 ng/g. Infants of mothers who reported alcohol consumption 
beyond 20 weeks’ gestation tended to have a higher mean total FAEE concentration 
in meconium compared with those infants whose mothers did not report alcohol 
after 20 weeks’ gestation (699 ng/g vs 638.5 ng/g). Of the eight mothers that 
reported drinking at least three units of alcohol on any one occasion beyond 20 
weeks of gestation, three had an infant whose meconium was positive for FAEEs 
using a cut off of ≥600 ng/g (concentrations 707, 847 and 996 ng/g respectively)  
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3.5.2 Analysis of meconium for ethyl glucuronide (EtG)  
740 meconium samples were sent for measurement of ethyl glucuronide (EtG) 
concentration, of which 712 samples were successfully analysed and were eligible 
for comparison with maternal and infant demographics. EtG concentration in 
meconium ranged from 0 to 8894.9 ng/g. EtG was detected in 293 samples, of 
which EtG concentration was below the LOQ (i.e., <10 ng/g) in 96. In the remaining 
419 samples no EtG was detectable. A cut off value of ≥30 ng/g EtG was designated 
a positive result.(116) Of the 197 samples in which EtG was detectable above the 
limit of quantification, 103 had an EtG concentration of ≥30 ng/g (“positive”). This 
represented 14.5% of the total number of analysable samples. For all the 712 
samples, the median concentration of EtG was 0 ng/g, and the IQR 0 to 12.4 ng/g. 
When EtG was detectable above the limit of quantification (n=197), the mean 
concentration was 162.1 ng/g (SD 871) and the median concentration was 32.2 
ng/g, IQR 17.9 to 55.8 ng/g.  
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EtG   
>30 ng/g  
  
(N=103)  
EtG   





(years) mean (SD)  
N=712  103  609    
29.8 (5.6)   29.4 (6.5)  29.9 (5.6)    
range  16 – 50.3  17.7 – 41.3  16.0 – 50.3    
% > 35 years  19.5  17.5  19.9  P=0.557  




N=696  100  596    
25.7   
(22.8 – 30.1)  
26.9  
(22.8 – 30)  
27.1  
(22.7 – 30.2)  
P=0.893  
range  15.2 – 59  17.7 – 44.6  15.2 – 59    
      
SIMD decile median 
(IQR)  
N=704  101  603    
3 (1 – 6)  2 (1 – 6)  3 (1 – 6.5)  P=0.371  
range  1 – 10   1 – 10  1 – 10     
      
Ethnicity  
(% White British)  
N=682  101  581    
80.2%  71.3%  81.8%  P=0.028  
      
Smoked during pregnancy  N=703  103  600    
17.9%  13.6%  18.5%  P=0.174  
      
Parous mums  
(%)  
N=699  101  598    
55.8%  52.5%  56.4%  P=0.516  
Mode of delivery  
(% vaginal)   
N=711  102  609    
61%  64.7%  60.4%  P=0.409  
      
Infant sex   
(% male)  
N=712  103  609   
51.3%  45.6%  52.2%   
Gestation (weeks)   
mean (SD)  
N=709  103  606   
38.9 (1.6)  38.8 (1.8)  38.9 (1.6)   
range  30 – 42  34 – 42  30 – 42   
Birthweight (g)  
mean (SD)  
N=710  103  607   
3373 (526)  3418 (524)  3365 (526) P=0.349  
range  1320 – 4905  2220 – 4750  1320 – 4905  
OFC (cm)  
Mean (SD)  
N=700  101  599   
34.6 (1.4)  34.8 (1.5)  34.6   
Range  29.5 – 41.2  31.8 – 41.2  29.5 -38.5   
APGAR score mean (SD)  N=703  100  603   
8.6 (1.2)  8.5 (1.1)  8.6 (1.3)   
range  0 – 10  4 – 9  0 – 10   
Table 3.9 Maternal and infant demographics in relation to meconium sample 
positive or negative for EtG 
 
There was no difference in either maternal age, BMI, parity, or SIMD score when 
meconium samples were grouped into EtG positive (n=103) or EtG negative (N=609) 
(Table 3.8). Infants whose meconium sample was positive for EtG were however 
less likely to have a mother who identified as white British (71.3 vs 81.8%, 
p=0.028).  
  




Figure 3.7 Socioeconomic profile in relation to meconium sample being positive for 
EtG.  
  
When SIMD 16 data were combined into deciles, roughly equal percentages of 
samples with EtG concentration ≥30 ng/g were obtained from babies whose 
mothers resided in deprived or relatively affluent postcodes (figure 3.7). A similar 
preponderance of positive EtG samples from SIMD decile 2 as was noted for FAEEs 
was observed, but numbers were too small to make useful statistical comparison.   
  
There was a lesser likelihood of the mother having smoked during pregnancy when 
the infant meconium was positive for EtG (13.6 vs 18.5%) but this difference did not 
reach statistical significance (Table 3.9). Of the mothers who stopped smoking in 
pregnancy (N=63), 7.9% infant meconium samples were positive for EtG, compared 
to 16.3% of samples from infants of mothers who never smoked. Thus, having stopped 
smoking during pregnancy was associated with a trend towards a lesser likelihood of 
PAE.  
  
Slightly fewer girls yielded meconium samples positive for EtG (45.6 vs 52.2%).  
Gestation was not different between infants whose meconium samples were 
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when meconium was positive for EtG but this difference did not achieve statistical 
significance (mean 3418 (SD 524) vs 3365 (SD 526) P = 0.349). This finding was 
mirrored by a marginal increase in mean OFC for newborns whose meconium was 
positive for EtG (mean 34.8 (SD 1.5) vs 34.6 (1.4) cm).  
  
Self-reported alcohol consumption as determined by confidential interview after 
delivery could be linked with 702 meconium samples. When infant meconium was 
positive for EtG, as defined by a concentration of ≥30 ng/g (N =103), 11 (10.7 %) 
mothers had reported alcohol consumption later than 20 weeks of pregnancy.  
When the concentration of EtG in infant meconium was <30 ng/g (N=599), 84 (14%) 
mothers had reported alcohol consumption after 20 weeks’ gestation. Thus, 
maternal self-report of any alcohol consumption in later pregnancy did not predict 
an infant meconium EtG concentration of >30 ng/g. In fact, infants of mothers who 
reported alcohol consumption beyond 20 weeks’ gestation tended to have a lower 
mean EtG meconium concentration compared with those infants whose mothers did 
not report alcohol consumption after 20 weeks’ gestation (20.1 ng/g vs 50.2 ng/g). 
Of the eight mothers that reported drinking a least three units of alcohol on any 
one occasion beyond 20 weeks of gestation, one had an infant whose meconium 
was positive for EtG using a cut off of ≥30 ng/g  
  
Correlation between FAEEs and EtG  
EtG concentration in meconium was compared with total FAEE concentration in the 
same sample. All meconium samples yielded some FAEEs but only 293 samples had 
detectable EtG, of which 96 were below the LOQ (Figure 3.8). There was no 
correlation between EtG and total FAEEs.  However, when only samples positive for 
both FAEEs (≥600 ng/g) and EtG (≥30 ng/g) (n=51) were considered (Figure 3.9) 
there was a weakly positive correlation (Pearson’s coefficient= 0.283, p 
value=0.044).    
































































































































































































































































3.5.3 Analysis of infant blood obtained on day five for phosphatidylethanol 
(PEth)  
510 blood spot samples were sent for assay of PEth concentration, of which 502 
samples were suitable for analysis. PEth was detectable in 262 (52%) samples, with 
concentrations ranging from 2.4 to 3991.6 ng/ml. The mean PEth concentration 
was 100.5 ng/ml (SD 416.3, median 5 ng/g). Comparison with maternal and infant 
demographics was made utilising two cut off values for PEth, ≥8 ng/ml and ≥20 
ng/ml (121, 137, 150).  
  
3.5.3.1 PEth cut off ≥8 ng/ml 
216 (43%) meconium samples had a total PEth concentration of ≥8 ng/ml. Results 
were highly skewed with a mean concentration of 120.7 ng/ml and a median 
concentration of 29.5 (IQR 16.3, 57.5) ng/ml).  
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  Blood spot 
card resulted   
(N=502)  
PEth   
>8 ng/ml  
(N=216)  
PEth   
<8 ng/ml  
(N=286) 
STATISTICS  
Maternal age (years) 
mean (SD)  
N=502  216  286   
29.6 (5.7)   29.3 (6)  29.9 (5.5)   
range  16 .1– 45.4  16.8 – 45.5  16.1 – 43.6    
% >35 years  19.3  22.7  16.1  p=0.102  
      
Maternal BMI  
(kg/m2) median 
(IQR)  
N=489  211  278    
27.3   
(22.9 – 30.1)  
27.8  
(23 – 31)  
27  
(22.8 – 30)  
p=0.301  
range  16.2 – 59  16.5 - 59  16.2 – 53    
      
SIMD decile median 
(IQR)  
N=497  214  283    
3 (1 – 6)  3 (1 – 6)  3 (1 – 7)  p=0.157  
range  1 – 10   1 – 10  1 – 10     
      
Ethnicity  
(% White British)  
N=482  209  273    
82.4%  86.6%  79.1  p=0.028  
      
Smoked during 
pregnancy  
N=497  215  282    
18.3%  22.3%  15.2%  p=0.047  
      
Parous mums  
(%)  
N=491  212  279    
59.5%  60.4%  58.8%  p=0.721  
Mode of delivery (% 
vaginal)   
N=502  216  286    
60%  61.6%  58.7%    
      
Infant sex   
(% male)  
N=502  216  286   
48.2%  46.8%  49.3%   
Gestation (weeks)  
mean (SD)  
N=500  216  284   
38.9 (1.6)  39 (1.4)  38.8 (1.8)   
range  28 – 42  34 – 42  28 – 42   
Birthweight (g)  
mean (SD)  
N=501  216  285   
3389 (540)  3428 (500)  3360 (567) p=0.052  
range  960 – 4905  1912 – 4886  960-4905  
OFC (cm)  
Mean (SD)  
N=492  213  279   
34.7 (1.6)  34.8 (1.5)  34.6 (1.7)   
Range  24.8 – 41.5  30.5 – 38.5  24.8 – 41.5   
APGAR score  
mean (SD)  
N=492  215  227   
8.6 (1.3)  8.6 (1.3)  8.6 (1.3)   
range  0 – 10  1 – 10  0 – 9   
Table 3.10 Maternal and infant demographics in relation to PEth concentration in 
dried blood spot cards (8 ng/ml cut off). 
 
 
There was no relationship between maternal age, parity, BMI, SIMD16 decile and 
the likelihood of the infant’s blood spot card having a PEth concentration ≥8 ng/ml 
or <8 ng/ml. There was a trend toward mothers of infants with a blood spot 
positive for PEth to be more likely to be over 35 years of age, 22.7 vs 16.1%, 
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p=0.102. When the infant blood spot card contained ≥8 ng/ml PEth, the mother 
was more likely to have self-identified as white British (86.6 vs 79.1%, p=0.028) and 
to have smoked during pregnancy (p=0.047).  
  
 
Figure 3.10 Socioeconomic profile in relation to blood spot sample being positive 
for PEth (8 ng/ml cut off).  
  
When SIMD 16 scores were combined into deciles, roughly equal numbers of those 
samples with PEth concentration ≥8 ng/ml compared to PEth samples with <8 
ng/ml were obtained from babies whose mothers resided in deprived or relatively 
affluent postcodes.  
  
Those infants with a positive blood sample as defined by PEth concentration ≥8 
ng/ml tended to be heavier at birth (p=0.052); there was however no difference in 
OFC. 
 
Self-reported maternal alcohol consumption was linked with 502 blood spot cards. 
Of those infants whose blood concentration of PEth was ≥8 ng/ml, 32 (14.8%) 
mothers reported alcohol consumption later than 20 weeks of pregnancy.  When 
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alcohol consumption after 20 weeks’ gestation; this difference was not significant 
(p=0.396).   
     
  
100 
3.5.3.2 PEth cut off ≥20 ng/ml  
148 (29.5%) of blood spot samples had a PEth concentration of ≥20 ng/ml. 
 Blood spot 
card resulted  
(N=502)  
PEth   
>20 ng/ml  
(N=148)  
PEth  
 <20 ng/ml  
(N=354)  
STATISTICS  
Maternal age (years) 
mean (SD)  
N=502  148  354    
29.6 (5.7)   28.7 (5.9)  30.0 (5.6)  p=0.023  
range  16 .1– 45.4  16.8 – 42.8  16.1 – 45.4    
% over 35 years  19.3%  18.9%  19.5%    
      
Maternal BMI (kg/m2) 
median (IQR)  
N=489  144  345    
27.3   
(22.9 – 30.1)  
28.4  
(23.2 – 32)  
26.9  
(22.7 – 29.9)  p=0.038  
range  16.2 – 59  16.5 – 59  16.2 – 53    
      
SIMD decile median 
(IQR)  
N=497  147  350    
3 (1 – 6)  2 (1 – 5)  3 (1 – 7)  p=0.026  
range  1 – 10   1 – 10  1 – 10     
      
Ethnicity  
(% White British)  
N=482  141  341    
82.4%  85.1%  81.2%  p=0.291  
      
Smoked during  
pregnancy  
N=497  147  350    
18.3%  24.5%  15.7%  p=0.021  
      
Parous mums  
(%)  
N=491  145  346    
59.5%  60%  59.2%  p=0.877  
Mode of delivery  
(% vaginal)   
N=502  145  354    
60%  64.2%  58.2%    
      
Infant sex   
(% male)  
N=502  148  354    
48.2%  47.3%  48.6%    
Gestation (weeks)  
mean (SD)  
N=500  148  352    
38.9 (1.6)  39.1 (1.3)  38.8 (1.8)    
range  28 – 42  34 – 42  28 – 42    
Birthweight (g)  
mean (SD)  
N=501  148  353    
3389 (540)  3457 (491)  3360 (557)  p=0.068  
range  960– 4905  1912 – 4886  960 – 4905    
OFC (cm) Mean (SD)  N=492  146  346    
34.7 (1.6)  34.9 (1.4)  34.6 (1.7)    
Range  24.8 – 41.5  30.5 – 38.5  24.8 – 41.5    
APGAR score mean (SD)  N=492  147  345    
8.6 (1.3)  8.6 (1.5)  8.6 (1.2)    
range  0 – 10  1 – 10  0 – 9    
Table 3.11 Maternal and infant demographics in relation to PEth concentration in 
dried blood spot cards (20 ng/ml) cut off  
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Mothers of infants whose blood spot card was positive for PEth (≥ 20 ng/ml) were 
younger (p=0.023) and their BMI was greater (p=0.038).  They were also more likely 
to have a lower SIMD score (p=<0.05). Slightly more mothers identified as white 
British among those infants whose blood spot card contained > 20 ng/ml PEth but 
this difference was not significant.  
  
 
Figure 3.11 Socioeconomic profile in relation to blood spot sample being positive 
for PEth (20 ng/ml cut off).  
  
When the infant’s blood spot sample PEth concentration was ≥20 ng/ml, the 
mother was more likely to have smoked (p=<0.0215).    
  
Infants with a PEth concentration of ≥20 ng/ml in their blood spot card tended to 
have a higher birth weight (3457 vs 3360 g, p=0.068). OFCs was marginally higher in 
infants with a positive PEth sample, however this was not of clinical significance.  
   
When the infant’s PEth concentration was ≥20 ng/ml 19 (12.8%) mothers reported 
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48 (13.6%) of mothers who declared alcohol consumption after 20 weeks’ gestation 
when the infant’s PEth concentration was <20 ng/ml.  
There was no correlation between PEth measured in dried blood spot cards and 
either FAEEs (Pearson co-efficient-0.019, p= 0.695) or EtG measured in meconium 
(Pearson co-efficient -0.009, P= 0.843) (Figures 3.12 and 3.13).        
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3.6 Sensitivity and specificity of alcohol biomarkers  
The sensitivity and specificity of the infant biomarkers were calculated using 
maternal self-report as the standard (Table 3.11).  
  
  Self-reported alcohol consumption in 
pregnancy at any time (n=328)  
Self-reported alcohol consumption in 
pregnancy after 20 weeks’ gestation 
(n=95)  
  sensitivity  specificity  PPV  NPV  sensitivity  specificity  PPV  NPV  
FAEEs 
>600ng/g  
41.2%  61.2%  48.2%  54.3%  43.1%  60.6%  14.6%  87.2%  
EtG 




EtG >30ng/g  
6.7%  92.2%  43.1%  53%  5.3%  92.4%  9.8%  86.2%  
    
PEth 
>8ng/ml  44%  57.1%  45.8%  55.3%  47.8%  57.3%  14.8%  87.6%  
PEth 
>20ng/ml  
29.3%  71.1%  46.6%  55.4%  28.4%  70.1%  12.8%  86.3%  
Table 3.12 Sensitivity, specificity, positive predictive value, and negative 
predictive value of infant biomarkers for PAE as ascertained by confidential 
postpartum maternal interview.  
  
Sensitivities of the various alcohol biomarkers ranged from 11.6% for EtG (> 30 
ng/g) to 47.8% for a PEth concentration of >8 ng/ml, and specificities ranged from 
57.1% (PEth >8 ng/ml) to 84.8% (EtG). Using a combination of total FAEEs >600 
ng/g and EtG >30 ng/g had a very high specificity for alcohol consumption either 
ever in pregnancy or only after 20 weeks’ gestation, but a very low sensitivity of 
6.7 and 5.3% respectively. 
 
Consistent with the lower reported incidence of drinking alcohol in later 
pregnancy, the positive predictive values of all biomarkers were less, and the 
negative predictive values higher for this reported pattern of drinking. The positive 
predictive value for self-reported alcohol consumption after 20 weeks’ gestation of 
both biomarkers being present in significant concentrations in meconium was 9.8%. 
Conversely, a combination of FAEEs <600 ng/g and EtG <30 ng/g had a high positive 
predictive value of 87% for no alcohol consumption after 20 weeks of gestation.   
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4.0 Discussion  
The primary aim of the study was to assess the pattern and prevalence of alcohol 
consumption in pregnancy by use of infant biomarkers in both meconium and dried 
blood spot cards. FAEEs were universally present in meconium, and in a 
concentration of >600 ng/g in 39.6% of samples. By comparison, EtG could be 
detected in only 41.1% of meconium samples and in a concentration of >30 ng/g in 
14.5%.  These figures were broadly comparable to the results of a smaller 
feasibility study conducted a couple of years previously in the same maternity unit, 
suggesting consistency of methodology(78). There was correlation between FAEEs 
and EtG when utilising the cut-off values of 600 ng/g and 30ng/g retrospectively 
(p=0.044), however there was no correlation between PEth and FAEE or EtG. This 
may be for a number of reasons, such as genetic variation, different metabolite 
pathways or instability of the biomarkers. However, it is more probable that this is 
due to different windows of detection of each biomarker, with PEth likely to 
represent the last few weeks of pregnancy, and FAEE and EtG representing beyond 
16-20 weeks(151). 
  
As one of the largest studies to date comparing self-reported maternal alcohol 
history with alcohol biomarkers in meconium as well as dried blood spot cards, this 
study demonstrates the feasibility of collecting and analysing meconium and infant 
blood spot samples on a large scale. Mothers were generally keen to take part and 
recruitment matched other studies which did not require informed written 
consent(152). This was likely due to a combination of researcher enthusiasm and 
study participation at place of care, both in the maternity unit (meconium) and at 
home (dried blood spot cards). By executing the study in the labour ward, 
postnatal wards and neonatal unit, and obtaining infant blood in the community 
coincident with routine newborn blood spot screening, the burden of participation 
for new mothers was greatly diminished. We had excellent cooperation from both 
hospital and community midwives, further enhancing recruitment and study 
participation.  
  
4.1 Recruitment  
Despite there being only a single researcher, more than 90% of eligible mothers 
were approached of whom only 6.8% declined to participate. Sample collection 
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was high; meconium samples were obtained from infants of 86.9% of mothers 
who had consented to the study and a dried blood spot card was obtained from 
79.5%.  Almost all (97.2 %) meconium samples were analysable, as were 75% of 
the dried blood spot cards. An issue arose in matching study numbers to a few 
meconium samples in the laboratory, attributable to laboratory use of only one 
identifier. To avoid erroneous results, we chose not to include results from these  
2.8% of meconium samples. The reason for not being able to analyse all of the 
blood spot cards which were collected was insufficient or no blood on the card. 
As part of the study protocol approved by REC, we did not ask for infants to have 
further heel pricks if the original heel prick for the routine newborn blood spot 
screening card did not continue to bleed sufficiently.  
  
Comparable studies have reported enrolment rates of 83% in a Ugandan 
population, 64% in a French population and 93% in Prince Edward Island, Canada. 
The latter study did not require written consent(117, 152, 153). It has been 
reported that the most accurate time for maternal self-report of alcohol 
consumption is around the time of pregnancy rather than when the child is aged 
6-8 years(79). Despite providing written consent, mothers may tacitly decline to 
participate by not providing infant samples, thereby potentially biasing the study 
population; other studies have not considered this. In order to establish the 
impact of this on the results it was hoped to compare demographic data from 
recruited mothers (with or without sample collection) to the entire maternity 
booking population by carrying out an anonymous download from PNBS, however 
this information proved not to be usable.  The only comparisons possible were 
data necessarily collected during screening of mothers for study eligibility. 
Mothers recruited to this study were not different in terms of age, SIMD16 score 
or mode of delivery from the general population and therefore the study 
population can be considered broadly representative.  
  
4.2 Alcohol biomarkers in relation to sociodemographic factors  
We found no associations between infant alcohol biomarkers and maternal age, 
parity or socioeconomic deprivation as measured by postcode of residence for 
FAEEs, EtG or PEth (cut off 8 ng/ml).  This is consistent with the findings of 
others in relation to FAEEs(118). There was no relationship with maternal age 
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when infant blood spot cards tested positive for PEth in studies in New Mexico, 
Texas, Uruguay, and Brazil(121, 138, 140). However, when mothers themselves 
were tested during pregnancy those mothers who tested positive for PEth were 
significantly older than those that did not test positive(154).  
  
In our study, there was no difference in ethnicity between mothers of infants 
whose meconium was or was not positive for FAEEs but when EtG concentration 
in meconium was >30 ng/g, the mother was less likely to be white British. This 
was the opposite of what we found when infant PEth was >8 ng/ml, where the 
mother was more likely to be white British. This difference was not significant 
for families with infant PEth concentrations >20 ng/ml. Women who self-
reported alcohol consumption in pregnancy were more likely to be white British 
(90.5 vs 71.6%) as seen in previous studies(155). The results may be the 
consequence of a type 1 error or might represent tactical refusal (although the 
latter is less likely since the association was inconsistent between FAEEs, EtG and 
PEth). It is also possible that non-white British women are less likely to declare 
alcohol consumption in pregnancy for fear of repercussions. Women who 
consented to take part in the study but who did not provide any infant samples 
tended to be less likely to be white British (70.8% vs 80.6%), perhaps a reflection 
of language difficulties or feelings of disempowerment. Given the inconsistency 
in results, and the widespread acceptance that white British women are more 
likely to consume alcohol in pregnancy, it would be inappropriate to draw 
conclusions from these data about any association between ethnicity and alcohol 
consumption in pregnancy.  
  
When infant meconium was negative for FAEEs or EtG, the mother tended to 
have been less likely to smoke in pregnancy (p= 0.071, p=0.174 respectively), 
however the opposite finding was seen in PEth results (p=0.047, p=0.021 
respectively). The former result was surprising as smoking is commonly 
associated with alcohol intake.  Smoking is routinely the subject of behaviour 
modification in pregnancy and mothers in Scotland are screened for smoking at 
booking both by self-report and CO breath tests, with either self-report or a CO 
≥4 ppm triggering referral to smoking cessation services(156-158).  In our 
population, mothers who did not provide an infant meconium sample tended to 
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be more likely to have smoked prior to pregnancy (30.8% vs 26.8% of mothers 
who did provide a meconium sample). Consistent with this, mean CO levels were  
2.9 ppm for those mothers who did not provide a meconium sample compared to  
2.5 ppm for those that did provide a sample. CO was poorly documented in the 
handheld notes (74% completed for recruited mothers); the focus of the analysis 
was therefore based on maternal self-report. It is possible that smoking mothers 
practised a degree of tacit refusal in regard to collection of meconium samples, 
but this cannot be concluded with certainty.  The opposite relationship with 
smoking was seen in PEth measured from dried blood spot cards on day 5; 
tactical refusal would have been more difficult as the dried blood spot cards 
were collected by the community midwife.  
  
Mothers who reported any alcohol consumption in pregnancy were more likely to 
have smoked than those that reported no alcohol consumption (20.1 vs 15.8%), 
but for self-reported alcohol consumption after 20 weeks’ gestation this 
association was reversed (13.3 % vs 18%).  This may suggest successful behaviour 
modification within the smoking population consequent upon smoking cessation 
services(158).  
  
We did not find any consistent association between socioeconomic status and 
infant alcohol biomarkers. When PEth was ≥20 ng/ml, mothers were more likely 
to be socioeconomically deprived, but this result was the opposite to self-
reported alcohol consumption. Women who self-reported alcohol consumption in 
pregnancy tended to be more affluent (mean SIMD16 score 4 vs 3). This is 
consistent both with findings from a Texan cohort, where higher PEth 
concentrations were measured from dried blood spot cards from infants of high 
to median income families, and with self-report within other UK populations(138, 
155). However, a similar study of 60 mother infant dyads measuring PEth found 
no such association(121). From our data it cannot be concluded that there is any 
association between biomarkers and socioeconomic status.  
  
Infants of mothers who self-reported alcohol consumption in pregnancy were 
heavier at birth, as were those infants whose meconium contained higher levels 
of FAEEs. Those infants whose dried blood spot card contained concentration of 
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PEth >8ng/ml and >20ng/ml also trended towards being heavier at birth (p= 
0.052, and p=0.068) respectively. This association was not found with EtG.  
Maternal diet, particularly olive oil consumption, may affect FAEEs in meconium 
and maternal diet will also affect infant birth weight, but we were not able to 
correct for these factors in this study(111). Infant polycythaemia and/or bruising 
at birth may also have affected PEth concentrations, but the former data were 
not collected and so could not be explored. There is concern that degradation of 
erythrocyte membranes caused by the freeze-thaw cycle in the management of 
blood samples in adults can lead to release of PEth(159).  This may explain 
previously reported variation in PEth in newborn dried blood spot cards 
compared to PEth measured in the mother at birth(140).  
  
4.3 Maternal self-report of alcohol consumption in pregnancy  
As part of the study protocol, newly delivered mothers completed a confidential 
interview including details of alcohol consumption prior to and during pregnancy. 
Alcohol consumption is commonplace in Scotland, and four in five mothers 
reported drinking alcohol out with pregnancy. Almost half of newly delivered 
mothers self-reported some alcohol consumption in pregnancy when they were 
asked in confidence by a single study researcher unrelated to the clinical team. 
This was considerably more than the 3% of mothers who reported having 
consumed alcohol in pregnancy included in a similar but smaller project in the 
same maternity hospital(78). In the latter case, alcohol consumption was sought 
in a more casual way, without use of the timeline follow back method. The self-
reported prevalence of alcohol consumption in pregnancy in the current study 
was higher than the 35% reported by mothers in Scotland in 2010 as part of the 
infant feeding survey(155). Within our study population, just under one in seven 
mothers stated that they had consumed alcohol after 20 weeks’ gestation. 
Amounts of alcohol reported were however very low, and consistently below the 
42 g per day reported in the literature as being reflected in raised infant alcohol 
biomarkers, which may explain why we did not see a correlation between self-
report of alcohol consumption and EtG concentration >30 ng/g(116). 
Interestingly, the prevalence of self-report of alcohol consumption in later 
pregnancy (13.8%) was very similar to the prevalence of meconium EtG >30 ng/g 
(14.5%).  




Our results indicate that within the Scottish pregnant population alcohol 
consumption is much more common than the reported global prevalence of 
alcohol consumption in pregnancy of 9.8% (95% CI 8.9-11.1%)(13). Our results are 
also high compared to Europe, which has the highest alcohol use in pregnancy 
compared to other WHO regions at 25.6% (95% CI 21.6-29.6%)(13). Goecke et al. 
described 21.2% of mothers in a German population self-reporting alcohol use in 
pregnancy, of whom the majority reported only low to moderate alcohol 
intake(79, 129, 153).  The method utilised to identify alcohol consumption is 
important; it is possible that mothers felt more confident talking to a researcher 
who was not related to the medical team providing clinical care. Having just 
delivered a healthy baby and knowing that there was to be an anonymised 
measurement of alcohol consumption through infant biomarkers may have 
allowed mothers more confidence in describing their alcohol consumption in 
pregnancy. Other workers have noted higher reported alcohol consumption soon 
after delivery, compared to later in the infant’s childhood. The importance of 
documenting alcohol consumption after delivery should not be underestimated as 
it provides an opportunity to provide interventions for both mother and infant for 
the current as well as for future pregnancies. Our data suggest that an alcohol 
history should be undertaken postnatally as well as at maternity booking(79). It is 
extremely unlikely that mothers will over-report alcohol consumption in 
pregnancy(83).  
  
While the prevalence of alcohol consumption was probably reasonably accurately 
reported, the described amounts of alcohol were very low and potentially 
underreported. As all reported volumes of alcohol were low, we could not 
categorise alcohol consuming mothers by the number of units of alcohol 
consumed. Although we planned to recruit purposively mothers who were known 
to be high consumers of alcohol (indeed we sought and were granted a 
substantial amendment to the study protocol to do this), we were unsuccessful in 
recruiting any such mothers. The reasons for this are not clear and may have 
included reluctance of the midwives to highlight these women to the study team. 
No known heavy alcohol consuming mother was identified and approached in 
regard to study participation.  




Mothers reported variation in consumption of alcohol depending on the stage of 
pregnancy. 31% of pregnancies had been exposed to alcohol prior to the mother’s 
knowledge of her pregnancy; as up to 50% of pregnancies are unplanned this fact 
is important and suggests that a public health focus needs to be on women of 
childbearing age reducing their general intake of alcohol and not only if they are 
contemplating pregnancy(160). Mothers reported less intake of alcohol between 
12-20 weeks of pregnancy compared to after 20 weeks’ gestation, which may be 
due to the perception that alcohol exposure after 20 weeks’ gestation is safer as 
the fetus has almost fully developed. Unfortunately, this is not true; CNS 
development beyond 20 weeks is critical, and so further work is required to 
determine how best to target health interventions(89, 90).  
  
4.4 Sensitivity and specificity of infant meconium alcohol biomarkers  
Assuming reasonable accuracy, postnatal self-report of alcohol consumption in 
pregnancy was utilised to calculate the sensitivity and specificity of the 
individual biomarkers using cut off values identified in the literature search.  In 
general, the sensitivity of individual infant meconium biomarkers was low, 
ranging from 11.6% to 43.1%. A total concentration of four FAEEs of > 600 ng/g 
had the highest combination of sensitivity (41.2% & 43.1%) and specificity (60.6 
and 61.2%) for detection of PAE. Bakhireva and Chan each reported a sensitivity 
of 100% for a total of four FAEEs, albeit a slightly different set of four FAEEs 
(ethyl palmitate, stearate, oleate and linoleate) and Kwak demonstrated a lower 
sensitivity of 22.2% for a total of nine FAEEs (ethyl laurate, myristate, palmitate, 
palmitoleate, stearate, oleate, linoleate, linolenate and arachnidonate) using a 
lower cut-off of 200 ng/g Himes reported a sensitivity of 64.9% for four FAEEs 
(91, 117, 119, 120). English used the same combination of ethyl stearate, oleate, 
linoleate and myristate as the current study (cut off 600 ng/g) but did not report 
a sensitivity. Among these previously reported studies specificities of FAEEs 
ranged from 13-73.6%, consistent with our specificity of 60.6% for alcohol 
consumed after 20 weeks’ gestation(117, 119, 120). 
  
EtG, reported by Himes et al. to have the highest sensitivity and specificity for 
PAE, demonstrated low sensitivity in our population (11.6-13.1%) although 
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specificity was high at 84 and 84.8%(120).  The combination of both FAEEs and EtG 
had very poor sensitivity (5.3%), but high specificity (92.4%) for self-reported 
alcohol consumption after 20 weeks’ gestation which probably reflects the 
relatively small amounts of alcohol consumed. The literature suggests the 
detection threshold of FAEE assay in meconium is around 40 g alcohol per 
week(119). Within our study population, the PPV of individual or combined 
biomarkers for alcohol consumption after 20 weeks’ gestation was low (9.8 – 
14.8%); since PPV is affected by the prevalence of the condition being sought this 
will not necessarily be comparable to other populations. As per Howlett et al., it is 
concluded that meconium biomarkers alone are not suitable as an PAE screening 
tool(92).  
  
4.5 Potential utility of measuring PEth in dried blood spot cards  
Parents proved willing to donate a small extra sample of their infant’s blood at 
time of routine newborn blood spot testing and a majority of blood spot cards 
contained an adequate sample. Measurement of PEth in blood spot cards has not 
previously been reported from the UK although there have been reports from 
both North and South America(101, 121, 138, 140).  American studies of PEth in 
the newborn have either used blood taken from the umbilical cord or coincident 
with newborn screening within the first 48 hours of life whereas in the UK the 
routine newborn blood spot card is obtained later, between 96 and 120 hours of 
age; results from our population and American studies would therefore be 
predicted to be different. It was anticipated that the concentration of PEth 
would be lower in blood spot cards taken on day five compared to samples 
obtained at birth or within 48 hours considering the time interval from alcohol 
exposure, but this was not what we found. A greater proportion of blood spot 
cards proved positive for PEth using cut offs of both 8 and 20 ng/ml than the 
proportion of meconium samples positive for either FAEE or EtG.  While PEth 
measured on day 5 may be a very reliable marker of PAE in the later stages of 
pregnancy, and a prevalence in excess of 40% (8 ng/ml) or almost 30% (20 ng/ml) 
a true reflection of maternal consumption, this seems unlikely. Other potential 
reasons for PEth concentrations to be higher than we predicted include variation 
in collection, analysis and/or storage. It is possible that the haemolysis 
associated with the shorter half-life of infant red blood cells and/or relative 
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polycythaemia results in increased PEth levels relative to the adult subject(161). 
This could potentially be explored by undertaking serial infant blood sampling 
during the first week of life and examining any relationship between infant PEth 
and haemoglobin concentration. Baldwin’s most recent publication also 
highlighted significantly higher PEth values (by a factor of approximately two) in 
newborns compared to their mothers, although she did not offer any explanation 
for this(140).  We found infants of higher birth weight to have higher PEth levels; 
the reason for this is not clear.   
 
Utilising a cut off of 20 ng/ml we found measurement of PEth to have a 
sensitivity of 28.4% and specificity of 70.1% for self-reported alcohol 
consumption after 20 weeks of gestation. Other researchers have reported PEth 
>20 ng/ml to have 32.1% sensitivity and 100% specificity for PAE, albeit from 
blood spot cards obtained at 48 hours of life(121). As with meconium biomarkers, 
the likelihood of a positive PEth result would have been reduced by the relatively 
small amounts of alcohol declared.   
  
One of the original aims of the study was to investigate whether stored dried 
blood spot cards might be able to be used to confirm retrospectively alcohol use 
in pregnancy when there is a clinical suspicion of FASD. Using cut off values of 
both 8 and 20 ng/ml, we found very low PPVs for alcohol consumption after 20 
weeks of pregnancy of 14.8 and 12.8% respectively. The NPV was higher, in 
excess of 85% for both cut off values, which might help to point the clinician 
towards other diagnoses, but it must be concluded that in general retrospective 
testing of retained newborn dried blood spot cards for PEth is unlikely to be 
clinically useful(64).  
  
4. 6 Study strengths and limitations  
Strengths  
Undertaken within a large single centre study population, this study had high 
rates of participation with a study population randomly selected and broadly 
representative of the maternity population as a whole.   
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Maternal alcohol history was obtained during a discrete and confidential 
interview using a modified timeline follow back method that made it as reliable 
as possible.  The researcher was not involved with the clinical care of either 
mother or baby, which may have engendered confidence in disclosure.  
  
Meconium samples were frozen in order to ensure stability, and freezing was 
mostly achieved soon after sample collection. Steps were taken to avoid 
contamination from bacterial colonisation leading to false positive FAEE 
results(112). While some blood spot cards may have been collected after the use 
of alcohol wipes or alcohol hand gel, this is unlikely to have contaminated the 
blood sample, as once dried, PEth levels in blood spot cards do not vary 
considerably(162).    
  
Limitations  
The study centre serves a relatively deprived population and so results may not 
be applicable to the Scottish or UK population as a whole. Carrying out this study 
across multiple sites would have allowed a more representative picture of the 
national population but would have required significantly more resource.  We 
had access to only limited sociodemographic data with which to assess the 
representativeness of the recruited study population; other demographics 
including education and marital status were not available.  
  
The study freezer was a distance from the site of care, resulting in some delays 
in sample freezing; a freezer on the post-natal wards would have made transition 
to freezer quicker. We did not record the exact time between sample collection 
and freezing, but even if recorded, this would have been the time the nappy was 
changed, and not the time that the meconium was passed. There is a small 
possibility that some meconium samples may have been affected by delayed 
transit to the freezer, resulting in either breakdown of FAEEs or increased 
production in samples with bacterial growth(112). The latter is however very 
unlikely in the newborn.   
  
For logistical reasons, meconium and dried blood spot samples were analysed in 
Italy rather than as originally planned at the University of Glasgow. Shipping 
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costs were significant, and so samples were shipped and analysed in only two 
batches. This led to a slight delay in analysis but should not have affected the 
results as samples remained frozen to ensure stability.  
  
Since the Scottish population is predominantly Caucasian, individuals were 
classified into only two groups, white British, and non-white British.  We were 
unable to study different minority ethnic groups as numbers were too small.   
  
One of the main weaknesses of this study is that, despite highlighting these 
mothers for recruitment at any time (including out with designated study sample 
collection days) we were unable to recruit any mothers with a known history of 
heavy alcohol consumption. Furthermore, a dose response could not be 
investigated due to the small volume of alcohol reported by those mothers who 
self-reported any alcohol consumption in pregnancy. This is in keeping with 
published literature which reports that lower consumers of alcohol are more 
likely to be inaccurate in their self-reporting compared to those with a high 
alcohol intake or abstainers(79).  
  
4.7 Potential impact on public health  
It has been shown than women have misconceptions with regard to the impact of 
alcohol on the health of the unborn child(160). In addition, it is estimated that 
50% of pregnancies are unplanned and so focussing public health information on 
those women planning pregnancy is unlikely to be completely successful(160). 
Within the UK, women who are given information with regards to cessation of 
alcohol intake rather than reduction in consumption are more likely to give up 
alcohol altogether(155).  The current study highlights that alcohol consumption is 
pregnancy occurs commonly across the population(92).  While infant biomarkers 
did not clearly relate to maternal self-report, it is possible that infant alcohol 
biomarkers could be a measure of harm to the infant, rather than simply 
reflecting the amount of alcohol consumed by the mother. Individual differences 
in alcohol metabolic pathways may favour production of toxic non-oxidative 
metabolites including FAEEs and EtG(108). Others have shown biomarkers in 
meconium to be associated with childhood outcomes(89, 90). 
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Alcohol consumption is strongly related to the price and availability of alcohol 
with a $0.01 increase in beer tax reducing the incidence of low birth weight by 1-
2%(163). Scotland has introduced minimum alcohol pricing and it is important to 
monitor the measure the impact of this upon PAE and FASD, but it is not clear at 
present that the best way to do this on a population basis will be via infant 
alcohol biomarkers.  
  
4.8 Review of the study aims  
At the outset of this project, we sought to answer a number of questions:  
  
1. What are the levels of FAEEs and EtG in meconium samples from singleton 
term and preterm infants born in a single maternity hospital in Glasgow?  
  
We found FAEEs to be universally detectable in meconium samples with 
concentrations ranging from 22.2 to 7549.8 ng/g. 39.6% of infants had >600 ng/g  
FAEEs in their meconium, a level described by previous workers as indicative of 
PAE. 21 infants demonstrated very high concentrations of FAEEs (>2000 ng/g). 
Such high concentrations have previously been described in a subgroup of babies 
born to opioid dependent, methadone-prescribed mothers, interpreted to 
indicate undisclosed significant alcohol consumption in pregnancy(11). EtG was 
detectable in 41.2% of meconium samples and the concentration was >30 ng/g in 
14.5% of cases. The prevalence of each meconium biomarker was similar to those 
found in an earlier pilot study in the same maternity hospital. When both FAEEs 
and EtG concentrations were positive (as defined by >600 ng/g and >30 ng/g 
respectively), there was a weak positive correlation between the two biomarkers 
(Pearson’s coefficient= 0.283, P-value=0.044). Preterm infants (< 37 weeks’ 
gestation) comprised 6.7% of the meconium samples, consistent with the national 
rate of preterm birth of 6.5%.  
  
2. What are the relationships between high levels of FAEEs and EtG in infant 
meconium and maternal age, parity, smoking, ethnicity, and socio-economic 
status?  
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High levels of FAEEs and EtG in infant meconium were not related to maternal 
age, parity, BMI, or socioeconomic status as measured by SIMD 16. In regard to 
FAEEs, mothers tended to have been less likely to smoke in pregnancy when their 
infant’s meconium was negative (14.7 vs 20%, p=0.071); for EtG this difference 
was less marked (13.6% vs 18.5%, p=0.174). Ethnicity was not associated with 
FAEEs in meconium, but for EtG there was a significantly less likelihood of the 
mother having identified as white British when the concentration of EtG in her 
infant’s meconium was >30 ng/g.  The relevance of this individual finding is not 
clear. 
  
3. What are the relationships between high levels of FAEEs and EtG in infant 
meconium and infant gestation, birth weight and head circumference?  
  
Infants with a total FAEE concentration in meconium of ≥600 ng/g tended to be 
of higher birth weight compared to those with FAEEs < 600 ng/g (3425 vs 3331 g, 
P= 0.032) but there was little variance in OFC (34.7 vs 34.6 cm). Infants with a 
total EtG concentration in meconium ≥30 ng/g compared to <30 ng/g did not 
have a significant difference in their birthweights, (birth weight 3418 vs 3365g, P 
= 0.034; OFC 34.8 versus 34.6 cm). There was no difference in gestation between 
groups positive or negative for either meconium or dried blood spot cards.  
  
4. What are the relationships between high levels of FAEEs and EtG in infant 
meconium and maternal alcohol intake during pregnancy as self-reported at 
booking and immediately post-delivery?  
  
Self-reported alcohol consumption at booking was poorly documented and 
therefore unable to be related to alcohol biomarkers in meconium. Mothers of 
infants with FAEEs ≥600 ng/g were not more likely to self-report alcohol intake 
beyond 20 weeks’ gestation than those whose infant’s meconium was negative 
for FAEEs (14.6% vs 12.8%, p=0.56) There was no relationship between EtG ≥30 
ng/g and self-reported alcohol consumption in pregnancy.  
  
5. What are the levels of PEth in dried blood spot cards from singleton term and 
preterm infants born in a single maternity hospital in Glasgow?  




PEth levels in the population ranged from 2.4 to 3991.6 ng/ml, with all cards 
having some detectable PEth. Within the study population the prevalence of PEth 
≥8 ng/ml and ≥20 ng/ml was 43% and 29.5% respectively.   
  
6. What are the relationships between high levels of PEth in dried blood spot 
cards and maternal age, parity, smoking, ethnicity, and socio-economic 
status?  
  
There was no relationship between a concentration of PEth of ≥8 ng/ml in infant 
blood on day five and maternal age, parity, or socioeconomic status.  Mothers of 
infants with PEth ≥8 ng/ml in their newborn blood spot card were more likely to 
have smoked (p=0.047) and to have identified as being white British (p=0.028). 
Mothers of infants with a concentration of PEth of ≥20 ng/ml in their blood spot 
card were slightly younger (p=0.023), had a higher BMI (p=0.038), lived in less 
affluent postcodes (p=0.026) and were more likely to have smoked during 
pregnancy (p=0.021).  There was no relationship between parity or ethnicity and 
PEth ≥20 ng/ml.  
  
7. What are the relationships between high levels of PEth in dried blood spot 
cards and infant gestation, birth weight and head circumference?  
  
There was no difference in gestation for infants with a significant concentration 
of PEth in a dried blood spot card, using cut offs of both 8 and 20 ng/ml. Infants 
with PETH ≥8ng/ml tended to be heavier (3428g vs 3360g, P = 0.052).  Infants 
with PEth ≥20 ng/ml tended to be heavier (3457 vs 3360 g, P = 0.068), and OFC 
tended to be greater (34.9 vs 34.6 cm).   
  
8. What are the relationships between high levels of PEth in dried blood spot 
cards and maternal alcohol intake during pregnancy as self-reported at 
booking and immediately post-delivery?  
  
When PEth concentration was ≥8 ng/ml 14.5% of mothers self-reported 
postnatally alcohol intake in pregnancy compared to 12.2% of mothers whose 
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infants had a PEth concentration of <8 ng/ml. For infants with a PEth 
concentration of ≥20 ng/ml 12.8% of mothers reported any alcohol intake beyond 
twenty weeks of gestation, compared to 13.7% when PEth was ≤20 ng/ml.  Most 
mothers self-reported very low amounts of alcohol consumption, with only three 
mothers reporting more than three units of alcohol on any one occasion. We did 
not therefore find a relationship between PEth in dried blood spot cards and self-
reported maternal alcohol intake during pregnancy.  
  
9. What is the relationship between levels of FAEEs and EtG in meconium and 
levels of PEth in dried blood spot cards in singleton term and preterm infants?  
  
There was no correlation between FAEE or EtG in meconium and PEth in dried 
blood spot cards.  
  
4.9 What could have been done differently?  
As this was a population study, the higher the number of recruited participants, 
the more accurate the calculation of sensitivity and specificity, and subsequent 
analysis of the sociodemographic groups would have been.  This could have been 
a larger study by recruiting over every day rather than every fourth day, and also 
by being carried out over two full twenty-week periods, thus not missing out on 
potential seasonal variation (Christmas festivities) in alcohol intake.  Researcher 
time could potentially have been saved, therefore allowing for more 
recruitment, by asking mothers to carry out questionnaires on tablet devices 
with electronic forms; this would have reduced the need to transcribe data, but 
may have reduced the reliability of responses compared to face to face interview 
with modified timeline follow back.  More analysis of data was not undertaken on 
the advice of a statistician, due to concerns about the introduction of type 1 
errors. Thus most data are presented in descriptive format.    
We tried to recruit high consumers of alcohol in pregnancy, including a 
significant amendment approval from REC, but were unsuccessful in this 
recruitment. Further study in this field needs to explore ways of recruiting this 
population in order to further validate biomarkers in both meconium and dried 
blood spot cards. Options might include carrying out targeted recruitment over a 
longer period or across multiple sites.  
     
  
121 
Logistically having freezers near the postnatal wards would have reduced any 
delay in the freezing of samples, as would having a larger, 24 hour on call 
research team. The latter would, however, have significantly increased costs. 
Having gained further understanding of PEth in dried blood spot cards through more 
recent publications, it would be useful to carry out serial PEth testing over the first 
week of life in infants to explore the effects of variation in haemocrit and bilirubin. 
These assays are not routinely performed from dried blood spot cards and would 
therefore require different samples to be obtained. The ethics of obtaining 
clinically unnecessary blood samples in the newborn would make this very difficult.  
4.10 Conclusions 
This large study has demonstrated that alcohol consumption in pregnancy in the 
west of Scotland is common, with almost half of newly delivered mothers 
reporting postnatally that they drank some alcohol in pregnancy. While a 
majority of mothers stop drinking alcohol once they realise they are pregnant, 
one in seven pregnant women delivering in the west of Scotland reports drinking 
some alcohol after 20 weeks of gestation. There was no clear association with 
maternal age, parity, ethnicity or socioeconomic status and consumption of 
alcohol in pregnancy, indicating that measures to reduce alcohol consumption in 
pregnancy must be widely targeted.  
  
FAEEs are commonly present in meconium, and EtG detectable in 41.2%; using 
cut off values of 600 and 30 ng/g respectively, alcohol biomarkers in meconium 
had poor PPV for any declared maternal alcohol consumption in pregnancy. A 
combination of FAEEs < 600 ng/g and EtG < 30 ng/g in meconium has a high NPV 
for self-reported alcohol consumption in pregnancy.  
  
Routine use of meconium biomarkers for detection of alcohol consumption in 
pregnancy is not currently justified. Similarly, retrospective testing of stored 
dried blood spot samples taken on day five of life cannot be recommended as a 
measure of assessing PAE.   
 
Neither infant alcohol biomarkers nor maternal self-report of alcohol 
consumption in pregnancy can be considered a gold standard for the detection of 
PAE.  




Further work is required to explore relationships between alcohol biomarkers in 
meconium and longer-term neurodevelopmental outcomes, as well as the role of 
measuring PEth in the newborn.  
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Appendix 2. Consent form  
  




Appendix 3. Data collection CRF  
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